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ABSTRACT
CDK2/cyclin A and CDK4/cyclin D1 are proven targets for cancer drug discovery. The
development of novel CDK inhibitors, with high selectivity, are being investigated by
targeting the cyclin binding groove (CBG) located on the cyclin, the regulatory subunit of
CDK. The CBG is a shallow area that is involved in signaling and the inhibition of cell
cycle CDKs via endogenous tumor suppressors. Currently, non-peptidic inhibitors are
being developed based on the recognition amino acid sequence, HAKRRLIF, of the Cterminal peptide sequence of the CDK inhibitor p21WAF1. Computational design and the
utilization of non-natural amino acids are being proposed in identifing small molecules to
replace the C-terminal amino acids (RLIF) via the REPLACE methodology. Such small
molecules, known as capping groups, have significant potential for converting the
octamer into a more drug-like molecule. The REPLACE methodology has been applied
and used to identify novel Ccaps to replace RLIF and these Ccaps have IC50 values in the
40-100 μM range against the cell cycle CDK/cyclin complexes of interest. Fragment
ligated inhibitory peptides (FLIPs) have been synthesized, coupled with a potent small
molecule N-terminal capping group (Ncap), and their binding affinities have been tested
using a Fluorescence Polarization (FP) assay. The results reported here enhance the
development of a selective, drug-like, cell permeable small molecule CDK cyclin groove
inhibitors by generating promising Ccaps and by identifying a novel approach to the
designing of potential partial ligand alternatives. Further, these results bring us closer to
achieving the ultimate goal of developing a novel class of cancer therapeutics based on
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cell cycle inhibition through cyclin dependent kinases.
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CHAPTER 1
INTRODUCTION
Cyclin dependent kinases (CDKs) play a major role in many cellular processes including
the mammalian cell cycle. CDKs are heterodimeric structures that contain two subunits,
the catalytic kinase and the regulatory cyclin.

This complex is responsible for the

phosphorylation of various substrates to tightly control cell proliferation. Other proteins
also regulate the cell cycle such as CDK inhibitors and tumor suppressor proteins. These
proteins, among others, work together to promote or suppress DNA replication and in a
perfect world this is done without disruptions or damage. However, through genetic or
environmental disturbance, many aspects of the cell cycle can be deregulated or disrupted
by mutation, overexpression, or amplification. Currently, several approaches are being
studied to identify potential CDK inhibitors to help restore regulation in cells with
uncontrolled proliferation. These include, but are not limited to, targeting the ATP
binding pocket on the kinase and the substrate recruitment site located on the cyclin. In
this chapter, the details of the cell cycle, altered functions of endogenous proteins and the
current therapeutic approaches will be discussed.

1.1 ROLE OF CDK/CYCLIN COMPLEXES IN THE CELL CYCLE
The mammalian cell cycle is the process in which cells replicate and divide to form two
daughter cells from a single parental cell. There are four consecutive phases of the cell
cycle that must occur in order for the cell to properly divide. These phases are Gap 1
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(G1), Synthesis (S), Gap 2 (G2), and Mitosis (M). Additionally, there is a resting phase
known as Gap 0 (G0) which is considered to be a sub-phase of G1 and contains nonproliferating cells1. During G1 phase the cell prepares for the entry into S phase by
expressing proteins required for S phase1. During S phase, DNA is replicated, in G2
phase the cell prepares for the entry into M phase, and during M phase the cell undergoes
cellular division1.
Each phase of the cell cycle is tightly controlled by specific CDKs. This protein
family contains more than 20 members and individual isoforms can be involved in
distinct cellular functions including both cell cycle progression and/or transcription.
During the cell cycle, CDKs complex with a regulatory cyclin and phosphorylate various
substrates to promote cell proliferation. During G1, CDK4 and CDK6 complex with the
D-type cyclins and these heterodimers are essential for progression through this phase1.
Late in G1, CDK2 binds to cyclin E to regulate the transition from G1 to S phase. In G2,
CDK1 complexes with cyclin A to promote entry into M phase and in M phase, CDK1
binds to cyclin B to help promote cellular division1 (Figure 1.1 and Table 1.1). CDK
protein levels remain constant throughout the cell cycle unlike the cyclins whose levels
oscillate to activate specific CDKs and to tightly control each phase of cell proliferation.
Unlike most others, the D-type cyclin (D1, D2, and D3) levels are maintained throughout
the cell cycle and their activity is regulated by growth factors/mitogenic stimulation1-2.
During transcription, two other CDKs (7 and 9) are active3. These CDKs promote
the initiation and elongation of nascent RNA transcripts by phosphorylating the carboxyterminal domain (CTD) of RNA polymerase II2a. CDK7 and 9 are subunits of TFIIH and
p-TEFb, respectively, in which they activate RNA polymerase II4. TFIIH is critical for
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stabilizing of the elongation factors and p-TEFb promotes productive elongation5.

FIGURE 1.1. STAGES OF THE CELL CYCLE The four stages of the mammalian cell cycle consist of Gap 1
(G1), Synthesis (S), Gap 2 (G2), and Mitosis (M) phases. G0 is a sub-phase of G1 and contains nonproliferating cells. During G1 phase, CDK4/cyclin D and CDK6/cyclin D complexes are active. During S,
G2, and M phases, CDK2/cyclin E and CDK2/cyclin A, CDK1/cyclin A, and CDK1/cyclin B are active,
respectively (Vermeulen, et al. 2003). [Figure reproduced with permission from John Wiley and Sons.]
TABLE 1.1. SUMMARY OF CDK/CYCLIN COMPLEXES DURING EACH PHASE OF THE CELL CYCLE.
CDK

Cyclin

Cell Cycle Phase

4

D

G1

6

D

G1

2

E

Late G1 into S

2

A

S

1

A

G2 into M

1

B

M

The G1/S phase transition is a critical point in the cell cycle. Cells either commit to
or abandon cell cycle progression. This process is complex and the retinoblastoma
protein (pRb) is at the center of all the action. pRb is a tumor suppressor protein whose
primary function is to tightly regulate cell proliferation during the G1 phase6. When
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hypophosphorylated, pRb is able to interact with a transcription factor, E2F-1, and also
with histone deacetylase-1 (HDAC1) to inhibit progression through the cell cycle2a.
When pRb is bound to E2F-1, the transcription of genes necessary for entry into S phase
is inhibited. When pRb is hyperphosphorylated by CDK4/6-cyclin D complexes late in
G1, the inhibitory effects of pRb are abolished and transcription is promoted.
Phosphorylation of pRb causes a disruption of the trimeric complex of pRb, HDAC1 and
E2F-11-2. E2F-1 is therefore released, able to bind with its heterodimeric partner, DP-1,
and together they direct the transcription of genes required for S phase. The cell can then
pass through what is known as the restriction point and from this point the cell is
committed to a single round of replication2a, 7.

As a result of E2F-1 promoting

transcription, cyclin E is expressed and is able to complex with CDK2 to maintain pRb in
a hyperphosphorylated state for the remainder of the cell cycle1, 2b.
During S phase of normal cells, the DNA of a cell must only replicate once and
prior to the completion of this replication, E2F-1 activity must be downregulated to avoid
potential apoptosis. CDK2/cyclin A phosphorylation of E2F-1 when bound to DNA is a
key event in the timely neutralization of E2F-1 activity2a. Phosphorylation of E2F-1
causes it to be released from the DNA and is therefore no longer able to function as a
transcription factor2a. The cell is then able to complete S phase and enter G2 where it
prepares for entry into and progression through mitosis.
There are four stages of mitosis (prophase, metaphase, anaphase, and telophase)
that result in the division of a single cell into two daughter cells1. Prophase is when the
chromosomes begin to condense inside the nucleus and the duplicated centrosomes
separate to form the poles of the mitotic spindle7. A stage prior to metaphase, known as
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prometaphase, is when the nuclear envelope breaks down and the chromosomes begin to
attach to the mitotic spindles. Metaphase involves the completion of this attachment and
alignment of the chromosomes in the center of the cell7.

To aid in the

metaphase/anaphase transition, CDK1/cyclin A and B phosphorylate the anaphase
promoting complex (APC)7. In turn the APC ubiquitinates cyclins A and B, marking
them for degradation, resulting in a repression of CDK activity which is critical for the
cell to exit mitosis and for the reentry into G17. Once in anaphase, the cell begins to exit
mitosis and the two sets of chromosomes split and approach the mitotic spindle poles,
meanwhile the nuclear envelope begins to reform as a precursor to telophase7.

In

telophase, the cell begins to divide in two and the final separation into daughter cells is
termed cytokinesis7.

1.2 ENDOGENOUS CDK/CYCLIN INHIBITORS
Along with the CDK/cyclin complexes, there are other regulators that are required for the
cell to successfully progress through the cell cycle. The regulation of cell proliferation is
aided by inhibitory proteins which bind to CDKs (CDKIs). There are two distinct
families of CDKIs, INK4 and Cip/Kip1. The INK4 family preferentially inactivates
CDK4/6 and consists of at least four members (p15INK4b, p16INK4a, p18INK4c, and
p19INK4d)1. These proteins bind to monomeric CDK to prevent their association with the
D-type cyclins1. The activities of the INK4 family results in the inhibition of the cell
cycle in G1 by disrupting the ability of CDK4/6 to phosphorylate pRb2b. Without pRb
phosphorylation, E2F-1 activity is inhibited and the cell never enters S phase2b. The
mechanism of action in which INK4 inhibitors bind and inhibit the CDK protein is
through binding near the adenosine triphosphate (ATP) binding site which alters its

5

conformation and allosterically prevents ATP from binding2b.
The Cip/Kip family inactivates the CDK/cyclin complexes of CDK1, CDK2,
CDK4, and CDK6. These inhibitory proteins include p21WAF1, p21Cip1, p27Cip2, and
p57Kip2 1. Each of these proteins contains a conserved sequence known as the cyclin
binding motif (CBM)2b. These proteins interact with the cyclin through this motif via
protein-protein interactions (PPI) at a shallow hydrophobic region on the cyclin known as
the cyclin binding groove (CBG). Other proteins (i.e. E2F-1, pRb, etc) also contain the
CBM and interact with the CBG in a similar manner prior to their phosphorylation by the
CDK/cyclin complexes. These interactions will be discussed in detail in Section 1.5.
The expression of p21WAF1 is under transcriptional control of p53, a tumor suppressor
protein1. The levels of p53 are generally kept low with in the cell however, when there is
DNA damage (replication errors, external damaging agents such as X-rays or UV light)
p53 levels accumulate enough for the expression of p21WAF1 to occur, resulting in cell
cycle arrest8.
To bring all of this into perspective, Figure 1.2 illustrates the stages and regulation
of the cell cycle along with a few of the numerous proteins involved. In brief, starting at
G1 (far bottom left) we have an INK4 protein bound to CDK4/6, inhibiting the
interaction with cyclin D. Upon mitogenic stimuli the transcription of cyclin D occurs.
When the INK4 protein is removed from CDK4/6, the kinases are able to complex with
cyclin D and upon phosphorylation by a CDK activating kinase (CAK; CDK7/cyclin H –
activates many CDK/cyclin complexes), the CDK4/6/cyclin D complexes become fully
activated. pRB is phosphorylated by CDK4/6/cyclin D complexes releasing E2F and
promoting the transcription of various genes necessary for S phase (i.e. cyclin E). CDK2
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associates with cyclin E to further phosphorylate pRb. CDK2 association with cyclin A
is required for DNA replication and this complex can be blocked by the Cip/Kip family
of CDKIs. Late in S phase, CDK1 binds to cyclins A and B, promoting APC (not shown
in the figure) to ubiquitinate cyclins A and B for their necessary degradation and the
progression of the cell cycle. Vermeulen, et al. (2003) explains this figure more in
depth1. The CDK/cyclin complexes and other protein activities can be inhibited by
Cip/Kip CDKIs by various pathways 2b.

FIGURE 1.2. OVERVIEW OF SOME ESSENTIAL PROTEINS INVOLVED IN CELL CYCLE REGULATION.
: phosphorylated site, : activation, and —׀: inhibition (Vermeulen, et al. 2003). [Figure reproduced
with permission from John Wiley and Sons.]

Also controlled by CDKs are checkpoints throughout the cell cycle.

These

checkpoints aid in the regulation of proliferation, ensure that the cell is in its optimum
state prior to the transition from one phase to the next, and are sensitive to problems
within DNA replication or within the cellular environment7. The first type of checkpoint
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is the restriction point late in G1. This checkpoint is sensitive to the physiological state
of the cell and its environment and with inappropriate mitogenic signaling, the cell will
not transition into S phase7. This restriction point is considered the “point of no return”
for the cell cycle1. It is at this point that the cell either commits to or abandons cell cycle
progression. The second type of checkpoint is the DNA damage checkpoint. G1, S, and
G2 phases each have this checkpoint which has the ability to block cell proliferation7. If
DNA damage is detected, the checkpoint will arrest the cell cycle to allow time for DNA
repair1. If the damage is too advanced the cell will undergo apoptosis7.
The third type of checkpoint is the DNA replication checkpoint. This checkpoint
has the ability to detect unreplicated DNA or malfunctioned replication machinery7. If
such problems arise, this checkpoint is able to aid in the stabilization of the replication
machinery to promote repair or to further DNA replication7. The last type of checkpoint
is the spindle assembly checkpoint. This checkpoint ensures that all chromosomes have
properly attached to the mitotic spindle prior to chromosome segregation7. If improper
attachment to the spindle is detected, the cell will arrest in mitosis1.

1.3 ALTERED FUNCTIONS OF CDK/CYCLINS AND ENDOGENOUS INHIBITORS IN
TRANSFORMED CELLS
CDKs are key players in regulating many important cellular functions (cell cycle control,
cell signaling, apoptosis, gene transcription, etc.) and their deregulation is associated with
numerous diseases, in particular cancer9. One of the most common deregulation events
during the cell cycle involves the CDK4/6-cyclin D-INK4-pRb pathway. This pathway is
ubiquitously disrupted in mammalian cancers2a,

9b

. The functional inactivation of the

tumor suppressor gene, pRb causes dysfunction of proteins that endogenously inhibit the
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proliferation1. Deregulation is most often seen in the G1/S phase CDKs (CDK2/4/6)
which occurs by the mutation of CDKIs (p16INK4a, p21WAF1, pRb etc.). These mutations
provide the means for transformed cells to override the G1 checkpoint resulting in
uncontrolled cell proliferation3, 10.
The CDKI p16 gene has been found to be altered in numerous tumor types and
inactivated by a number of mechanisms (deletion, point mutation and hypermethylation)12

. With altered p16, cells lack the ability to inhibit CDK4/6-cyclin D resulting in pRb

being hyperphosphorylated and unable to sequester E2F-1, thus promoting uncontrolled
cell proliferation1, 11. This inappropriate entry into S phase and overactivation of E2F-1
should induce apoptosis11.

Altered p16 has been noted in glioma, mesothelioma,

pancreatic, and many other cancer types1.
The CDK4 gene has been found to be amplified and CDK4 protein overexpression
has been noted in multiple cell lines, particularly in breast cancer1, 12. A study conducted
on CDK4 null mice determined that the animals were resistant to mammary carcinomas,
the continual presence of CDK4 and cyclin D1 was critical in retaining tumor cell
proliferation, and the catalytic function of CDK4/cyclin D1 complex is mandatory to
sustain the tumorigenic potential of breast cancers cells12. Mutant cyclin D1 is able to
bind to the appropriate CDKs and to the CDKIs p21Cip1 and p27Kip1 however this mutated
cyclin lacks the ability to activate the kinase12.
Cyclin D1 is the most ubiquitously expressed cyclin and is present in many cell
types and tissues9b. Its gene amplification has been observed in bladder, lung, colon, and
many other malignant cancers and cyclin D1 is known to be a critical regulator of breast
cancer1-2. Cyclin D1 upregulation is often associated with the loss of p16 function and
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results in increased levels of CDK4 available to complex with D-type cyclins and
endogenous CDKIs2a.

CDK4/6-cyclin D1 complexes promote the activation of

CDK2/cyclin E and the phosphorylation of pRb2a. The increased activity of CDK2/cyclin
E, as a result of the CDK4/6-cyclin D-INK4-pRb pathway being deregulated, further
causing inappropriate levels of E2F activity, leading to uncontrolled cell proliferation.
CDK 1 and 2 have been noted to be overexpressed in a subset of colon adenomas, cyclin
E is amplified and/or overexpression in breast, colon, and many other cancers, and both
cyclin A and E have been found to be overexpressed in lung carcinoma1.

1.4 ATP COMPETITIVE CDK INHIBITORS
There are many approaches to the design of kinase inhibitors. These include blocking of
the Adenosine Tri-phosphate (ATP) binding pocket, blocking the substrate recruitment
site, and stabilizing kinases in their inactive conformations13. This section focuses on
kinase inhibitors that preferentially block the ATP binding pocket. This pocket is well
defined and the generation of small molecules inhibitors to block this hydrophobic pocket
has been studied for many years13c. The ATP binding pocket is composed of five main
sites, (1) central purine binding site, (2) solvent accessible surface, (3) ribose binding site,
(4) phosphate binding region, and (5) hinge region13a. Each of these sites are important
for the binding affinity of ATP, (which is involved in many intermolecular interactions
including van der Waals, hydrophobic and hydrogen bonding) and are used as guides for
the structure based design of inhibitors13a, 13c.
CDKs and other proteins have been determined to be critical regulators of the
eukaryotic cell cycle13b, as discussed in Section 1.1. Gain-of-function and/or loss-offunction of such proteins during the cell cycle (i.e. cyclins, endogenous CDK inhibitors,
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and other substrates) cause a snowball effect on the regulatory events of the CDKs
leading to the transformation of cells13b. CDK4/6 have been determined to be frequently
amplified or overexpressed in many tumor types and their inhibition would block cell
proliferation and avert the transcription of genes necessary for cell cycle progression 13b.
Also, it has been observed that the absence of CDK2/cyclin E complex in both
transformed and untransformed cells does not affect cell cycle proliferation14. This raises
the concern that specific targeting of CDKs may not be of best interest for cancer
therapeutics, due to redundancies in kinase activity14. There are many kinase inhibitors
with single and/or multiple targets in the cell cycle and such targets include cell cycle
CDKs, transcriptional CDKs, or both15. An alternative strategy that does not target the
catalytic domain would evade the problems of redundancy in kinase activity.
PD0332991 (Palbociclib) has recently been approved by the Food and Drug
Administration (FDA) as a “Breakthrough Therapy”16. Breakthrough therapy allows a
drug to be used as treatment while the remainder clinical trials are conducted16.
CDK4/cyclin D1 has been proven to be disrupted in many tumor types by overexpression
and/or amplification and blocking the ability of CDK4/cyclin D1 to phosphorylate
substrates necessary for cell cycle progression, is a viable approach to treating cancer15,
17

. PD0332991 is highly selective for CDK4/6 with IC50 values of 11 nM and 15 nM,

respectively, and exclusively induces G1 arrest17-18. When tested against a panel of
serine, threonine, and tyrosine kinases, PD0332991 (Figure 1.3) showed very little to no
activity against kinases other than CDK4/618.
In retinoblastoma (Rb)-positive cancer cells, it was observed that with treatment of
PD0332991 (0.011 µmol/L) there was an induction of G1 arrest, a reduction in tumor
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growth, and in human xenograft models there was tumor regression15,

19

.

When

PD0332991 was tested against Rb-negative cancer cells there was no activity15,
concluding that PD0332991 has the ability to halt cancer cell growth in patients with Rbpositive cancers17, 20. A study was conducted to determine if drug resistance would occur
with continued use of PD0332991. Colo-205 human colon carcinoma tumor xenografts
in mice were negative for resistance after treatment for 14 days with PD0332991 with
doses of 75-150 mg/kg and tumor regression was observed in some tumors at a dose of
37.5 mg/kg18. In primary bone marrow myeloma cells, G1 arrest was potently induced
with doses as low as 0.3 µM and with higher doses (greater than 5 µmol/L) apoptosis was
induced21.

FIGURE 1.3. CHEMICAL STRUCTURE OF PD0332991. Chemical structure of 6-acetyl-8-cyclopentyl-5methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one.

When PD0332991 was used in combination with dexamethasone, apoptosis was
enhanced with treatment for 48 hours of 0.01µM of drug in bone marrow myeloma
cells21.

In disseminated human myeloma xenografts, tumor growth was completely

inhibited21. More recently, when used in combination with Femara (Letrozole), an antihormonal agent, there was an increase in progression-free survival of about 3.5 fold20. A
Phase 3 clinical trial is currently recruiting for first-line treatment of postmenopausal
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women with ER-positive/HER2-negative advanced breast cancer. Treatment will be
conducted with PD0332991 in combination with Letrozole and Letrozole alone.
There are multiple CDK inhibitors targeting the G1 and S phases that are currently
in clinical trials, however, PD0332991 is the only orally bioavailable drug that has high
specificity for CDK4/6 kinases17. During Phase 1 and 2, the most common dose-limiting
toxicities were myelosuppression, nausea, vomiting, diarrhea, and fatigue17. Neither
vascular thrombotic nor neurological adverse events were observed with PD0332991
treatment as has been observed with other CDK inhibitors in clinical trials17.
A second CDK inhibitor that targets the ATP binding pocket is Flavopiridol
(alvocidib, HMR1275; Figure 1.4). This compound is active against multiple kinases but
is known to be most potent against the transcriptional CDK, CDK9, relative to other
kinases15.

FIGURE 1.4. CHEMICAL STRUCTURE OF FLAVOPIRIDOL. Chemical structure of 2-(2-chlorophenyl)-5,7dihydroxy-8-((3R,4S)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one.

Early studies showed that flavopiridol potently inhibited CDK2 and CDK4 with
IC50 values between 50-120 nM22. In MCF-7 (p53 and Rb proficient) and MDA-MB-468
(p53 and Rb deficient) cells, G1 arrest was induced, proving that the action of
flavopiridol is independent of p53 and Rb22. MCF-7 cells showed a significant loss in
cyclin D levels without altering the levels of cyclin A, cyclin E, CDK2, or CDK4. These
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results led to the conclusion that flavopiridol inhibits CDK2/4 kinase activity resulting in
G1 arrest22. However, studies conducted in head and neck squamous cell carcinoma
(HNSCC) cell lines showed that flavopiridol caused a significant decrease in CDK1/2
activity with IC50 values between 43-83 nM23.
Fischer and Gianella-Borradori (2003) summarizes the potency and selectivity
profile of flavopiridol.

They summarized that against the transcriptional kinase

CDK9/cyclin T1, flavopiridol is most potent with an IC50 value of 0.006-0.01 µM. In
2010, studies show that flavopiridol treatment resulted in the inhibition of the C-terminal
domain of RNA-polymerase-II causing an inhibition in transcription resulting in
apoptosis24. When tested against CDK1/cyclin B and CDK4/cyclin D1 flavopiridol
showed IC50 values of

<0.1 µM, and against CDK2/cyclin A, CDK2/cyclin E,

CDK7/cyclin H, and other kinases (epidermal growth factor receptor, protein kinase C,
etc.) flavopiridol has IC50 values of ≥0.1 µM25.
A study was conducted on a panel of human tumor xenografts26. Flavopiridol was
proven to be highly potent against prostate and less potent against melanoma, breast,
lung, and ovarian cancers26.

In nude mice containing prostate cancer xenografts

(PRXF1369), flavopiridol showed a maximum tolerated dose (MTD) of 10 mg/kg/day
and a tumor growth delay of 30 days26. In human promyelocytic leukemia (HL-60)
xenografts, animals experienced complete regression and remained disease free for
several months. In human B-cell follicular lymphoma (SUDHL-4) xeongrafts, animals
underwent major or complete regression and were disease free for more than two months
at 7.5 mg/kg concentrations27.
Flavopiridol was the first CDK inhibitor to enter clinical trials. As a single-agent,
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in Phase 2 clinica trials, flavopiridol induced pro-inflammatory syndrome at doses of 50
mg/m2 in patients with advanced cancers28 and showed to have no effect on advanced
colorectal and non-small cell lung cancer as well as several other cancer as first line
treatment29. Flavopiridol does have a minimal response as a second-line therapy in
endometrial adenocarcinoma and advanced renal cell carcinoma30. When flavopiridol
was used in combination therapy, significant antitumor activity was observed. In the
administration of flavopiridol after gemcitabine there was a 10-15 fold increase of
apoptosis in pancreatic, gastric, and colon cancer cell lines31.
A third ATP-competitive inhibitor is JNJ-7706621(Figure 1.5). This compound is
a multi-targeted/pan kinase inhibitor that targets CDKs and Aurora kinases32. As stated
previously, CDKs play a central role in the cell cycle and their activity is dependent upon
the regulatory subunit, cyclin. Aurora kinases play an important role during mitosis, in
regulating chromosomal movement and organization33.

FIGURE 1.5. STRUCTURE OF JNJ-7706621. The chemical structure of 1-(2’,6’-difluorobenzoyl)-5-amino3-(4’aminosulfonylanilino)-1,2,5-triazole.

JNJ-7706621 is a 1,2,4-triazole-3,5-diamine derivative and is moderately potent
inhibitor of CDK1 and 2 (moderately potent against CDK4) and Aurora kinases A and
B33-34. When tested against a large number of other protein kinases JNJ-7706621 had
little to no activity15. A CDK1 kinase assay was conducted, in the presence of 5 µM ATP
and JNJ-7706621 showed to have an IC50 value of 17.12±1.03 µM33. Against PC3
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prostate cancer cells and HCT-116 colon cancer cells, JNJ-7706621 showed potent
inhibition with IC50 values of 0.112±0.012 µM and 0.189±0.042 µM, respectively. It was
observed that JNJ-7706621 resulted in a delay in cell cycle progression in G1 and cell
cycle arrest was observed at the G2/ M phases in human cancer cells33-34.

It was

determined that JNJ-7706621 is a potent antiproliferative agent against numerous cancer
cell types, irrespective of p53, retinoblastoma (Rb) or P-glycoprotein levels33. However,
JNJ-7706621 has poor solubility and studies have been conducted on potentially utilizing
nanoparticles as non-toxic vehicles for its delivery34.

1.5 NON-ATP COMPETITIVE CDK INHIBITORS
A different approach to the development of CDK inhibitors is to target alternative sites
other than the ATP binding site35. Targeting the ATP binding site has proven to be
beneficial in the development of cancer therapeutics. It is well known that the ATP
binding pocket is conserved across all kinases and present in many proteins that are
involved in numerous cellular functions.

There are risks in potentially inhibiting

transcriptional CDKs by causing effects on normal cells which may account for the
toxicities observed with clinically evaluated CDK inhibitors3. The ultimate goal in novel
chemotherapeutic development is to identify a target that is unique to a specific cancer
cell or when inhibited will allow the cancer cell to be sensitized to cell death. It has been
established that many biological processes are regulated through protein-protein
interactions (PPI) and theoretically, if identifiable, PPIs could be blocked specific
proteins or pathways would be inhibited.
During the cell cycle the cyclin binding groove (CBG) of the cyclin subunit is
involved in the recruitment of various substrates for phosphorylation35.
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The CBG

recognizes a short peptide sequence known as the cyclin binding motif (CBM). Figure
1.6 illustrates a CDK2/cyclin A heterodimer. This motif is conserved in many cell cycle
substrates and inhibitory proteins and has been identified to interact specifically with the
CBG through PPIs. Substrates involved in the cell cycle are recognized by the CBG
through the CBM, are recruited into close proximity of the groove, and are
phosphorylated by the active CDK/cyclin complex.

FIGURE 1.6. CDK2/CYCLIN A/P27 TRIMERIC COMPLEX. Illustration of a CDK2/cyclin A complex with
the ATP binding site located on the kinase (red) and the cyclin groove on the cyclin (blue). p27 (yellow)
is shown interacting with both the ATP binding site and the cyclin groove.

Often times, the negative regulators of the cell cycle (p21, p27, etc.) are inactivated
resulting in upregulation of CDK activity. This can cause an override of the phase
checkpoints (described in Section 1.2) and may lead to uncontrolled cell proliferation and
to the transformation of cells. Cellular response through the inhibition of the CBG is
greater in transformed cells because E2F-1 is frequently deregulated in such cells and has
been reported to induce apoptosis in combination with CDK2/cyclin A inhibition36.
Transformed cells depend on CDK2/cyclin A to decrease the activity of E2F-1 to avoid
the induction of apoptosis in late S phase10b.
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Due to the CBM being conserved across the Cip/Kip family members (Section 1.2),
selective inhibitors can be designed to block the CBG and inhibit the activity of the
CDK/cyclin complexes resulting in the induction of apoptosis in transformed cells.
Peptides composed of naturally occurring amino acids are useful for lead compounds in
discovering new drug therapies but generally speaking are limited as therapeutics by their
undesirable pharmacokinetic profiles. These are caused by their poor permeability (blood
brain barrier, cell membrane, etc.) and lack of metabolic stability including proteasemediated degradation37. Currently, HAKRRLIF, based on the C-terminal domain of
p21WAF1, is being used in structure based design to develop non-peptidic inhibitors for
CDK2/cyclin A and CDK4/cyclin D1 references.
Previously mentioned in Section 1.4, selective inhibition of kinases may not be of
best interest due to redundancies in the kinase activity. An approach, targeting the CBG,
reduces the possibility of such problems because it is the protein kinase that is known to
be redundant14 not the cyclin. Cyclin groove inhibitory compounds should be selective
due to cyclins A, D, and E being the only cyclins containing a functional binding groove
and thus are potential targets for non-ATP competitive CDK inhibitors38. CDK2/cyclin
A and CDK4/cyclin D1 are validated anticancer drug targets, targeting the CBG of these
kinases provides selectivity, and the kinases involved in other cellular processes will not
be affected38. However, it has been determined that potent CDK2/cyclin A inhibitors
generally are significantly less effective against CDK4/cyclin D138.

Due to these

differences Liu, et al. (2010), set out to determine which structural variants between
cyclin A and D1 might affect the potency of CDK inhibitors. In terms of the CBG, there
are three major sites of the hydrophobic cleft that are involved the binding of
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HAKRRLIF: 1) a primary hydrophobic pocket that interacts with Leu6 and Phe8 (the 6th
and 8th amino acids of HAKRRLIF)38 2) a secondary hydrophobic pocket that interacts
with Ala2 and 3) an acidic region, located between the two lipophilic pockets, that forms
ionic contacts with the basic amino acids, Arg4 and Arg538.
To determine the differences in the CBG of cyclin A and D1, their crystal
structures were overlaid and the following variants were determined (Figure 1.7). On the
left-hand side of Figure 1.7, the black chemical structure represents Leu6 and Phe8 of
HAKRRLIF. The residues of the primary hydrophobic pocket of the CBG are L214
(Leu) and V60 (Val) for cyclin A and D1, respectively. The residues E220 (Gln) and
D216 (Asp) make up the acidic region for cyclin D1 and E66 and T62 (Thr) for cyclin A.
As for the secondary hydrophobic pocket, the amino acids W217 (Trp) and W63
constitute this pocket for cyclin A and D1, respectively. The other residues shown are
considered to be non-peptide contacting residues.

These residues are structurally

different between Cyclin A and D1. I281 (Ile) of cyclin A is exchanged for Y127 (Tyr)
in cyclin D1 (also seen in the ribbon representation right-hand side of Figure 1.7) within
residue region of 116-136 and these differences lead to altered conformations of the CBG
in cyclin D1 compared to cyclin A38. Cyclin D1 is able to accommodate larger functional
groups in the primary hydrophobic pocket because this region is larger and contains an
extension, compared to cyclin A38. Figure 1.8 illustrates these structural variants using
the solvent accessible surface of each cyclin. As a whole, it was determined that cyclin
D1 contains a narrower secondary pocket, a shallower yet larger primary hydrophobic,
and a less acidic region at Asp283 compared to cyclin A38. The variation in the CBG
between cyclin A and D1 is significant enough to cause differences in binding affinities
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between CDK inhibitors discussed below.

FIGURE 1.7. COMPARING THE CYCLIN BINDING GROOVE OF CYCLIN A AND CYCLIN D1. (Left) Overlay
crystal structure of cyclin A2 (PDB 10KV; Carbon atoms green) and cyclin D1 (PDB 2W96; Carbon atoms
orange). (Right) Overlay of the ribbon representation of both cyclin A2 (Red) and cyclin D1 (yellow). An
inhibitory peptide (blue) is shown interacting with the CBG. Residues 116 through 136 are where the
largest structural differences are located between these two cyclins. [Reprinted with permission from Liu,
S., J. K. Bolger, et al. (2010). "Structural and Functional Analysis of Cyclin D1 Reveals p27 and Substrate
Inhibitor Binding Requirements." ACS Chemical Biology 5(12): 1169-1182.. Copyright 2010 American
Chemical Society.]

Non-peptidic inhibitors are being developed by the REPLACE (REplacement with
Partial Ligand Alternatives through Computational Enrichment) strategy (Figure 1.9).
This strategy is an effective way to iteratively convert peptidic analogs involved in PPIs
to non-peptidic, drug-like small molecules3, 10b. Computational chemistry is utilized to
identify partial ligand alternatives (PLAs) by docking small molecule fragments into the
cyclin groove and evaluating their interactions compared to that of the native ligand35. In
brief, REPLACE is carried out by the truncation of the N-terminal amino acids of the
lead peptide and computationally designed PLAs are coupled through solid-phase
synthesis. These FLIP compounds are then tested in a competitive binding assay and
those with substantial activities against CDK/cyclin complexes of interest are further
optimized by the truncation and replacement of the central and C-terminal amino acids
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with the aim of generating a cell permeable, non-peptidic inhibitor.

FIGURE 1.8. COMPARING THE PRIMARY AND SECONDARY HYDROPHOBIC POCKETS OF THE CBG OF
CYCLIN A AND CYCLIN D1. Solvent accessible representations of the cyclin binding groove. (Left) Cyclin
A2 was determined to have a more acidic region around GLU220 of the CBG causing ARG4 of the CBM
to interact differently in cyclin A2 compared to cyclin D1. (Right) Cyclin D1 was determined to have a a
shallower and an extended primary hydrophobic pocket and a narrower secondary hydrophobic pocket
compared to cyclin A2. These structural differences promote different binding affinities for CBG
inhibitors. [Reprinted with permission from Liu, S., J. K. Bolger, et al. (2010). "Structural and Functional
Analysis of Cyclin D1 Reveals p27 and Substrate Inhibitor Binding Requirements." ACS Chemical
Biology 5(12): 1169-1182.. Copyright 2010 American Chemical Society.]

FIGURE 1.9. REPLACE METHODOLOGY. A schematic overview of the REPLACE strategy. The lead
peptide is truncated at the N-terminus and computationally designed partial ligand alternatives (PLAs) are
coupled through solid-phase peptide synthesis. These FLIP compounds are then tested in a competitive
binding assay and those with substantial activities are further optimized by the truncation and replacement
of the central and C-terminal amino acids resulting in a cell permeable, non-peptidic inhibitor.

Advantages of the REPLACE strategy are that non-peptidic fragments can be
identified for extensive and shallow PPIs while negating the need for highly sensitive
binding assay and should be applicable in the replacement of individual amino acids or
peptide sequences to generate pharmaceutically adequate lead molecules10b.
REPLACE has previously been utilized to replace the N-terminal amino acids
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(HAKR) with fragment molecules (Ncaps) to create FLIPs3, 10b. Much progress has been
made in the replacement of these amino acid residues. The most potent Ncap to date is 1(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (35DCPT) which has
decreased the overall charge of the peptidic sequence by eliminating the charged Arg4
residue and has improved potency compared to other FLIP compounds10b. When coupled
to RLIF (SCCP 5773; Table 1.2), the FLIP compound showed an IC50 value of 4.0±0.6
µM against CDK2/cyclin A and 27.3±3.40 µM against CDK4/cyclin D13,

35

. These

values were directly compared to an optimized peptide sequence that contains the Cterminal amino acids RRLIF of HAKRRLIF3. This pentapeptide has an IC50 value of 1.4
µM against CDK2/cyclin A and 16.1 µM against CDK4/cyclin D13.
TABLE 1.2. Summary of Previously Reported N-terminal Capping Groups Coupled with RLIF.

SCCP
ID

R1

R2

R3

R4

W

X

Y

Z

CDK2/cyclin A
IC50 (µM)

CDK4/cyclin D1
IC50 (µM)

5773

Cl

H

Cl

Me

N

N

N

C

4.0±0.6

27.3±3.40

5774

H

Cl

H

Me

N

N

N

N

11.5±3.3

12.0±2.06

Many heterocyclic compounds were designed for the replacement of HAKR and
tested against these two cyclins. Such compounds include but are not limited to triazole,
pyrazole, pyrrole, furan, imidazole, and thiazole3, 35. Variants of each heterocycle were
generated with halogens at either the three and five position or at the fourth position of
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the phenyl ring3. These substitutions were demonstrated to have a significant impact on
the binding affinity of these FLIP compounds as measured using a fluorescence
polarization assay.
potent3.

The phenyltriazole compounds were determined to be the most

A second phenyltriazole FLIP, SCCP 5774, (4-chlorophenyl triazole-RLIF;

4CPT; Table 1.2) was shown to have greater activity in cyclin D1 compared to SCCP
5773 with IC50 values of 11.5±3.3 µM and 12.0±2.06 µM against CDK2/cyclin A and
CDK4/cyclin D1, respectively3, 35. The narrower secondary pocket of cyclin D1 cannot
accommodate the 3,5-dichlorophenyl ring of SCCP 5773 to the same degree as the 4chloro substituted analog3. This data demonstrates that critical residues of the octamer
can be replaced with small drug-like molecules while decreasing overall charge and
increasing potency9a.
Viable Ncaps have been identified and fragment alternatives are now desired for
the replacement of the central and C-terminal amino acids, RLIF, to complete the
conversion of HAKRRLIF into a more drug-like molecule.

A library of bis(aryl)

compounds were generated and it was determined that Ccaps containing a 3phenoxybenzylamine core structure were the most effective at mimicking the binding
mode of Phe83. Structural modifications were conducted to determine how activity could
be optimized further and halogens were added at various positions of the aromatic ring
contacting the primary hydrophobic pocket3. It was determined that the FLIP compound
containing a fluorine at the four position of the bis(aryl) Ccap, with 4CPT as Ncap and an
arginine linker (SCCP 5823) was the most potent against CDK2/cyclin with an IC 50 value
of 18.1±4.0 µM3 (Table 1.3). However, neither this FLIP nor others generated have been
potent against CDK4/cyclin D1.
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TABLE 1.3. Summary of Two Previously Reported Fragment Ligated Inhibitory Peptides.

SCCP
ID

R1

X

R2

R3

R4

R5

CDK2/cyclin A
IC50 (µM)

CDK4/cyclin D1
IC50 (µM)

5823

4CPT

N

H

H

F

H

18.1±4.0

>200

5926

35DCPT

N

H

F

F

H

>180

>180

The replacement of Leu6 and Phe8 is imperative for the conversion of HAKRRLIF
to a more drug-like molecule based on the work of Liu et al. (2013). Small molecule
replacements, to enhance the binding affinity of the FLIP molecule, are desired and the
following chapters describe further applications of the REPLACE strategy for the design
of such novel Ccaps. Towards this goal, computational design has been utilized for
structure- and pharmacophore-based design of Leu6 and Phe8 replacements. In addition
non-natural arginine isosteres have been incorporated to retain and/or enhance the
binding affinity of FLIP compounds while making them more drug-like. Achieving this,
will be progressive towards the complete replacement of HAKRRLIF resulting in more
drug-like compounds that should have enhanced cell permeability and carry this project
into the next phase of in vivo testing of such compounds.
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CHAPTER 2
DESIGN OF FRAGMENT LIGAND INHIBITORY PEPTIDES FOR THE REPLACEMENT
OF THE C-TERMINAL AMINO ACIDS OF THE CYCLIN-BINDING MOTIF
In the effort to convert HAKRRLIF into a more drug-like molecule by utilizing the
REPLACE methodology, the replacement of the N-terminal amino acids (HAKR) has
been undertaken and significant progress has been achieved. The most effective FLIP
compound for the replacement of HAKR to date is 1-(3,5-dichlorophenyl)-5-methyl-1H1,2,4-triazole-3-carboxamide (35DCPT)-RLIF (SCCP 5773; Table 1.2).

However,

further replacement of the C-terminal residues (RLIF) is required for the complete
conversion of HAKRRLIF into a cell permeable, non-peptidic inhibitor. A library of
bis(aryl) ether fragments, coupled with Ncap-Arg5-Leu6 (i.e. the 5th and 6th amino acids
of HAKRRLIF), has shown activity in the mid to high micromolar concentrations in
inhibiting CDK2/cyclin A. The most potent of these compounds was found to be 4-(4fluorophenoxy)pyridin-2-yl)methanamine coupled to 1-(4-chlorophenyl)-5-methyl-1H1,2,4-triazole-3-carboxamide (4CPT)-RL (SCCP 5823, Figure 2.1) which has an IC50
value of 18.1±4.0 µM against CDK2/cyclin A but no appreciable activity towards
CDK4/cyclin D1. Further optimization to obtain a more effective C-terminal capping
group is required for the conversion of HAKRRLIF to a more drug-like, cell permeable
small molecule. Currently the Ccaps that have been developed are weakly or not active
against CDK2/cyclin A or CDK4/cyclin D1.

A new approach for the design and

development of such novel Ccaps for the replacement of RLIF of the octamer is desired.
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To achieve this, computational design has been used to identify small molecules of
interest via structure-based design with Discovery Studio 3.0 and the web-based
pharmacophore search software AnchorQuery™.

FIGURE 2.1. CHEMICAL STRUCTURE OF SCCP 5823. Chemical structure of 1-(4-chlorophenyl)-N-((S)1-(((R)-1-(((4-(4-fluorophenoxy)pyridin-2-yl)methyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-5guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5823).

2.1 PICOLINAMIDE AND BENZAMIDE NCAP SCAFFOLDS
To continue with the replacement of the amino acid residues of HAKRRLIF,
picolinamide and benzamide Ncaps were used to perform substructure searches of online
libraries for diverse small molecules that can be used to replace the entire octapeptide
(HAKRRLIF) or be used to design potential Ccaps for the replacement of RLIF. The
picolinamide and benzamide Ncaps (Figure 2.2) have been modeled and show to have
similar intermolecular interactions as the triazole derivative 35DCPT with the CBG at
Trp217 and Glu254. These two interactions are of importance to help retain the binding
affinity for the FLIP compounds.

When tested in a competitive binding assay,

picolinamide and benzamide showed adequate IC50 values comparable to those of
35DCPT. When coupled with RLIF, 35DCPT (SCCP 5773; Table 1.2) has IC50 values of
4.0±0.6 µM against CDK2/cyclin A and 27.3±3.4 µM against CDK4/cyclin D1. To date
the most potent picolinamide derivatives, coupled with RLIF, are 6-methoxypicolinamide
(SCCP 524) with an IC50 value of 70.1±7.9 µM against CDK2/cyclin A and 5-(piperazin1-ylmethyl)picolinamide (SCCP 5856) with an IC50 value of 42.7±12.02 against
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CDK4/cyclin D1. Also, to date the most potent benzamide derivative is 3-hydroxy-4(piperazin-1-ylmethyl)benzamide coupled to R(β-Leu)N-Methyl-Phe-NH2 (SCCP 5966)
has been shown to have IC50 values of 3.91 µM and 4.93 µM against CDK2/cyclin A and
CDK 4/cyclin D1, respectively. Changing the C-terminal amino acids from RLIF to R(βLeu)N-Methyl-Phe-NH2 increased the binding affinity for this FLIP compound 1.5-fold.

FIGURE 2.2. CHEMICAL STRUCTURES OF N-TERMINAL CAPPING GROUPS. Chemical structures of (left)
1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (35DCPT), (middle) picolinamide,
and (right) benzamide.

A library search using these Ncap as scaffolds has identified potential Ccaps of
which the small molecules are commercially available. This allows rapid assessment of
activity without investing the time, expense and effort in the laboratory required to
synthesize these compounds. Using this approach, small molecules identified to replace
HAKRRLIF are required to have at least one of the desired hydrogen bonding (Hbonding) interactions in the secondary hydrophobic pocket (Trp217 and/or Glu254) to
help retain the binding affinity of HAKR and have good complementarity with the
primary hydrophobic pocket for the replacement of RLIF.

Of the small molecules

identified, those with the best prediction will be sourced commercially and their activities
tested in a competitive binding assay.

2.1.1 RESULTS AND DISCUSSION
Previously, validation exercises for LigandFit as a high throughput docking method were
conducted to determine the predictability and reproducibility of computationally
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designing Ccaps. Along with a negative control, native ligands of both cyclin A and
cyclin D (35DCPT and 4CPT, respectively) were used as positive controls and docked
into the CBG of CDK2/cyclin A.

In conjunction with this docking, a number of

parameters were altered such as a) the energy grid (force field that calculates the ligandreceptor interaction energies), b) the minimization sphere (helps minimize the molecular
energy), and c) the number of poses (orientation of how the fragment potentially may fit
into the pocket) generated. For each of the result sets, the poses generated that were
superimposable with the native ligand crystal structure (correct poses; within 2
Angstroms), whose scoring functions (used to provide a consistent interpretation of the
data generated) yielded the negative control to be within the top 25 poses, and whose
scoring functions yielded the most number of correct poses within the top 25 poses were
further studied. The CFF (consistent force field) energy grid with the minimization
sphere on, the generation of 20 poses per native ligand, and the scoring functions of
LigScore2_Dreiding, -PLP1, and –PLP2 were determined to be the optimized parameters
for the LigandFit docking method (Table 2.1).
Picolinamide and benzamide Ncap scaffolds were used in a substructure search of
the ChemBridge® library for potential small molecules to replace HAKRRLIF or to aid
in the design of novel Ccaps. The validated optimized parameters were used in the
docking of the resulting compounds from the search.
fragments

is

One of the most interesting

N-(5-guanidino-1-(naphthalen-2-ylamino)-1-oxopentan-2-yl)benzamide

(BZ01; Figure 2.3) which contains a benzamide Ncap, a naphthalene Ccap, and an
arginine in the Arg5 position.
The benzamide Ncap, of this small molecule, forms an H-bond with Trp217 and the
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arginine ion-pairs with Asp283 and H-bonds with Glu254. In addition, the naphthalene
Ccap has good complementarity with the primary hydrophobic pocket. This compound
also ranks well in the overall scoring functions. LigScore2_Dreiding, -PLP1, and –PLP2
were previously determined to be the optimal scoring functions for the prediction of
potent small molecules. This compound is ranked within the top twenty- five percent of
all ligands docked with scores of 5, 56.06,and 55.88 for LigScore2_Dreiding, -PLP1, and
–PLP2, respectively (Table 2.2). With the observed intermolecular interaction and the
resulting scores, this molecule was expected to have activity against both Cyclin A and
D1. However, upon testing in the FP assay this fragment was found to be weakly
binding. Possible further optimization of the naphthalene group would provide better
binding.
TABLE 2.1 VALIDATION RESULTS FOR THE SELECTION OF OPTIMAL PARAMETERS FOR THE LIGANDFIT
DOCKING METHOD
Energy Grid

Dreiding

CFF

PLP1

No. of correct poses
3,5-DCPT

7

10

7

No. of correct poses
4-CPT

3

-

1

Negative controls in
top 25

-PLP1(5), -PLP2(3),
PMF(10), DOCK
SCORE(4)

-PMF (21)

-PLP1(1), -PMF(10)

Best scoring functions

LigScore2_Dreiding, PLP1,
-PLP2, DOCKSCORE

LigScore2_Dreiding,
-PLP1, -PLP2

LigScore2_Dreiding,
-PLP1, -PLP2,
DOCKSCORE

3,5-DCPT(rank of top
25 correct/closer
poses for the best
scoring function)

LigScore2_Dreiding,
-PLP1, -PLP2, and
DOCKSCORE (22,23,24,
25,26,27), Jain (22)

LigScore2_Dreiding,
-PLP1, and –PLP2
(31,32,33,38)

LigScore2_Dreiding,
-PLP1, and –PLP2
(39,40,41),
DOCKSCORE
(23,28,29,30)

-

-PLP1 (11,14,15),
Jain (11),
-PMF
(11,12,13,14,15)

-PLP1 (6), -PMF
(8,21)

4-CPT (rank of top
25 correct/closer
poses for the best
scoring function)
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ASP283

GLU254

TRP217

FIGURE 2.3. POTENTIAL SMALL MOLECULE FOR THE REPLACEMENT OF HAKRRLIF (BZ01). N-(5guanidino-1-(naphthalen-2-ylamino)-1-oxopentan-2-yl)benzamide modeled into the CBG of cyclin A
(BZ01; PDB 2UUE). As shown by the light green dotted lines, this small molecule hydrogen bonds and
ion-pairs with the CBG at TRP217, GLU254, and ASP283, respectively.

The most potent benzamide Ncap coupled with RLIF contains a 4methoxypiperidine (SCCP 5851) at the 4 position of the aromatic ring. This functional
group and others can easily be added to the benzamide to help retain activity against
Cyclin A and D1. Various groups also may be added to the naphthalene Ccap to
potentially promote further intermolecular interactions and increase the binding affinity.
TABLE 2.2. The SCORING FUNCTION SUMMARY FOR N-(5-GUANIDINO-1-(NAPHTHALEN-2-YLAMINO)-1OXOPENTAN-2-YL)BENZAMIDE [BZ01], METHYL 3-BENZAMIDO-5-((5-METHYL-3-PHENYLISOXAZOLE-4CARBOXAMIDO)METHYL)BENZOATE [BZ02], (E)-N-(3-((1,5-DIMETHYL-3-OXO-2-PHENYL-2,3-DIHYDRO1H-PYRAZOL-4-YL)AMINO)-3-OXO-1-PHENYLPROP-1-EN-2-YL)BENZAMIDE [BZ03].

Scoring Function

BZ01

BZ02

BZ03

LigScore2_Dreiding

5

5.38

5

-PLP1

56.06

101.82

68.54

-PLP2

55.88

90.39

63.07

A second fragment that is of interest is methyl 3-benzamido-5-((5-methyl-3phenylisoxazole-4-carboxamido)methyl)benzoate (BZ02; Figure 2.4) which contains the
benzamide Ncap, a 5-methyl-3-phenylisoxazole-4-carboxamide Ccap, and benzoate in
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place of Arg5. The benzamide Ncap H-bonds with Trp217 and this molecule scores
within the top twenty-five percent with scores of 5.38, 101.82, and 90.39 for
LigScore2_Dreiding, -PLP1, and –PLP2, respectively (Table 1.1).

FIGURE 2.4. POTENTIAL SMALL MOLECULE FOR THE REPLACEMENT OF HAKRRLIF (BZ02). Methyl 3benzamido-5-((5-methyl-3-phenylisoxazole-4-carboxamido)methyl)benzoate [BZ02] modeled into the
CBG of cyclin A (PDB 2UUE).

The scores for this fragment rank higher than BZ01 however, BZ02 may not retain
the binding affinity as well. The benzoate linker is unable to ion-pair with Asp283
similarly to Arg5 and the 5-methyl-3-phenylisoxazole-4-carboxamide Ccap does not
mimic the binding mode of Leu6 and Phe8 well. However, the lack of these interactions
has not been determined to be detrimental to the binding affinity and thus would be worth
testing to determine the activity this fragment has against both CDK2/cyclin A and
CDK4/cyclin D1.
Another compound that is of interest is (E)-N-(3-((1,5-dimethyl-3-oxo-2-phenyl2,3-dihydro-1H-pyrazol-4-yl)amino)-3-oxo-1-phenylprop-1-en-2-yl)benzamide

(BZ03;

Figure 2.5). This molecule contains the benzamide Ncap, a 4-amino-1,5-dimethyl-2phenyl-1H- pyrazol-3(2H)-one Ccap and 3-phenylacrylaldehyde in place of Arg5. This
fragment H-bonds with Trp217 and ranks within the top twenty-five percent of the
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ligands docked. This molecule has scores of 5, 68.54, and 63.07 for LigScore2_Dreiding,
-PLP1, and –PLP2, respectively (Table 1.1). Compared to BZ01 this fragment also ranks
higher in all scoring functions however, this molecule is also not expected to retain the
binding affinity of HAKRRLIF. The 3-phenylacrylaldehyde linker acts more as a spacer
and theoretically does not interact with the CBG similarly to Arg5. The 4-amino-1,5dimethyl-2-phenyl-1H-pyrazol-3(2H)-one Ccap looks to mimic the binding mode of
Leu6 and Phe8 better than that of BZ02 and potentially may help retain the binding
affinity of these residues.
In addition to potential replacements for HAKRRLIF, this exercise helped
generate ideas for the design of novel Ccaps. From BZ01, it is evident that a fused ring
system, like naphthalene (Figure 2.6), fits well into the primary pocket and many analogs
of this Ccap can be generated. A few modifications can be alkylation or halogenation to
help the Ccap reach further into the pocket and potentially enhance the binding mode of
these analogs. Another compound identified from ChemBridge® was an adamantane
derivative. This compound is also adequate for this pocket and would most likely mimic
the binding mode of Phe8 but this group is bulky and may not be suitable for the Leu6
position.

Modifications of the adamantane can also be generated by alkylation or

halogenation to retain/enhance the binding affinity of the FLIP compound incorporating
this Ccap. An alkylated furan group may also be of interest for the replacement of LIF.
The five-membered ring will provide a different geometry in the pocket which may
benefit the binding affinity and help generate further SAR.
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FIGURE 2.5. POTENTIAL SMALL MOLECULE FOR THE REPLACEMENT OF HAKRRLIF (BZ03). (E)-N-(3((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)-3-oxo-1-phenylprop-1-en-2-yl)
benzamide [BZ03] modeled into the CBG of cyclin A (PDB 2UUE).

FIGURE 2.6. CHEMICAL STRUCTURES OF CCAP SCAFFOLDS. Chemical structures of adamantane, furan,
and naphthalene amine derivatives as scaffolds for Ccap designs.

Obtaining the IC50 values for BZ02 and BZ03 will beneficial to the investigation of
prospective replacements for HAKRRLIF. BZ01 was determined to be weakly binding
and shows that a fused ring system alone may not be sufficient in the primary pocket and
that further optimization of this group is needed to regain activity. The ideas generated
from this exercise for potential Ccaps have been taken into consideration and the future
design of Ccap may incorporate such scaffolds.

2.1.3 MATERIAL AND METHODS
Small molecules identified through the ChemBridge® library search that are of most
interest, have been/will be purchased and tested in a competitive binding assay. The
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Florescence Polarization (FP) assay was used to evaluate the small molecule’s ability to
compete with a florescence labeled ligand, known as tracer, against CDK2/cyclin A and
CDK4/cyclin D1.

This assay monitors the changes in molecular interactions in

fluorescent molecules39. This type of analysis is advantageous because it allows for
direct and rapid measurements of the ratio of bound and free tracer peptide39 The FP
assay is conducted in solution allowing for true equilibrium analysis into the low
picomolar range and real time measurements39.
The theory behind the FP assay is that small fluorescent molecules become excited
via plane-polarized light. When the tracer is bound to the protein, the rotation is slower
and the emitted light is in the same plane at the excitation energy therefore, giving off a
higher fluorescence39.

Polarization is then calculated by measuring the molecular

rotation during the time between excitation (488 nm) and emission (535 nm)39. The
equation used for calculating the relative polarization (mp) is as follows:

EQ 2.1

The IC50 values are then determined by using a logarithmic regression of the relative mp
values versus the testing concentrations3.
The FP assay was conducted as previously reported3. In brief, buffer solution,
tracer peptide, positive and negative controls, the protein, and the FLIP compound are
combined in 384-well plates and the fluorescence of each well is measured by a Beckman
Coulter DTX 880 Multimode detector. The C-terminal pentapeptide of the endogenous
p21WAF1 (RRLIF) was previously tested in the FP assay and showed IC50 values of 1.4
μM and 16.1 µM for CDK2/cyclin A and CDK4/cyclin D1, respectively3. The binding
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affinity for CDK2/cyclin A and CDK4/cyclin D1 of the Ccaps generated will be directly
compared the binding affinity of these native ligands.

2.2 PHARMACOPHORE BASED DESIGN
Studies using the AnchorQuery™ pharmacophore search technology software have been
conducted for the development of potential Ccaps. AnchorQuery™ is an online software
program that runs from a webserver that allows pharmacophore features of a peptide
sequence to be specified and small molecules from a Multi-Component Reaction (MCR)
database that closely mimic the pharmacophore of interest be returned by the software for
further analysis. For this study, HAKRRLIF and the receptor (cyclin A) were uploaded
into the software and the desired pharmacophore queries of the C-terminal amino acids
(RRLIF) were varied to allow the maximum number of potential small molecules to be
returned by the software. Example pharmacophore queries include aromatic, hydrogen
bond donor, hydrogen bond acceptor, hydrophobic and positive-ion searches. Two types
of anchors (leucine/valine and phenylalanine) were used to aid in the preservation of side
chains functionality required for binding in the peptide context. An anchor is defined as a
functional group that chemically mimics a specific amino acid40. Other filters that may
be set include specific types of reaction used for synthesis, molecular weight in Daltons,
rotatable bond count, or the root mean squared deviation (RMSD; to minimize the
compounds returned by the software to those containing the conformation within the
query features that were selected) can be varied to help obtain fragments that are of most
interest.

The molecules returned by the software are all accompanied with the

information regarding their synthesis via MCR. Using this strategy, fragments identified
should closely match the pharmacophore of the native ligand in order to retain critical
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peptide binding determinants and increase the probability of finding an active Ccap.

2.2.1 RESULTS
Using this approach, Ccaps of interest have been identified and synthesized. One
of the most interesting Ccaps predicted by the software is 2-amino-N-ethyl-4-methyl-N(3-phenylpropyl)pentanamide (Ccap in SCCP 6005 and 6014; Table 2.4), Figure 2.7
illustrates this capping group superimposed with HAKRRLIF in the primary hydrophobic
pocket of Cyclin A. From this image, it is evident that the phenyl propylamine group
closely mimics the interactions of Phe8. The predicted binding mode of this group
suggests that when incorporated as a FLIP, this compound will aid in retaining the
binding affinity of RRLIF in the primary hydrophobic pocket. This synthesis of this
small molecule was suggested by AnchorQuery™ to be achieved using a reductive
amination MCR however, it was determined that synthesis via a two-step process had
better versatility and allowed facile incorporation of the Ncap and arginine residues. This
fragment, 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)pentanamide, was synthesized
via reductive amination followed by peptide synthesis (Scheme 2.1) and purified through
semi-preparative High Performance Liquid Chromatography (prep-HPLC). Prep-HPLC
and Mass Spectroscopy (MS) data can be found in Appendix A.
In addition to 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)pentanamide, other
variations have also been synthesized (Table 2.3). Each of these Ccaps have been
coupled to 35DCPT-Arg and either Leu or Beta-Leu (Figure 2.8). The variations (Table
2.3) include different length alkyl chains, and a hydrogen or ethyl group at the R position.
The natural leucine was used in the synthesis of the analogs with a propyl alkyl chain
(SCCP 6004, 6005, and 6014). Natural leucine, with the amine group on the alpha
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carbon, helps position these Ccaps in a binding mode similarly to that of the native
ligand, aids in the positioning of these fragments in the primary hydrophobic pocket, and
potentially aids in retaining the binding affinity of LIF. Non-natural β-leucine was used
in the synthesis of the analogs with either methylene or ethylene alkyl chains (SCCP
6000, 6001, 6002, and 6003). Beta amino acids contain an additional methylene group,
placing the amine group on the beta carbon, which theoretically should adjust for the
shorter alkyl chains and help position the fragments in the primary hydrophobic pocket to
closely mimic the native ligand.
TABLE 2.3. SUMMARY OF CCAPS IDENTIFIED VIA THE ANCHORQUERY™ SOFTWARE.

SCCP ID

n1

n2

R

CDK2/Cyclin A
IC50 (µM)

CDK4/Cyclin D1
IC50 (µM)

6000

1

1

H

>180

>180

6001

1

1

Et

>180

>180

6002

1

2

H

>180

>180

6003

1

2

Et

85.62

>180

6004

0

3

H

57.74

>180

6005

0

3

Et

>180

>180

6014

0

3

Et

90.19

>180
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FIGURE 2.7. NOVEL C-TERMINAL CAPPING GROUP FOR THE REPLACEMENT OF LIF. 2-amino-N-ethyl4-methyl-N-(3-phenylpropyl)pentanamide superimposed with LIF of the CBM in the primary hydrophobic
pocket. This small molecule mimics the exact poses of LEU6 and PHE8 in this pocket and thus several
derivatives of this small molecule have been designed and tested in a competitive binding assay to
determine their binding affinity.

Following the peptide synthesis of Ncap-Arg-Leu/βLeu the Ccaps of Table 2.3
were coupled followed by the deprotection of these guanidine protecting group of
arginine and the purification of these FLIP compounds through prep-HPLC. The HPLC
data and MS data of the purified FLIPs are located in Appendix A. As shown by the
HPLC traces, the FLIPs are 88-98 percent pure, by UV, and the MS results confirm the
identity of the desired FLIP. Once the FLIP compounds were characterized, their binding
affinities were tested by FP assay as described in Section 2.1.4. The competitive binding
assay determined that the ethyl phenylethan-amine Ccap coupled to 35DCPT-R-β-L
(SCCP 6003, Table 2.3) has an IC50 value of 85.62 µM and the phenylpropyl amine and
ethyl phenylpropyl amine Ccaps, coupled with 35DCPT-RL (SCCP 6004 and 6014
respectively), have an IC50 values of 57.74 µM, and 90.19 µM against CDK2/cyclin A,
respectively. All other FLIP compounds in Table 2.3 have IC50 values greater than 180
µM against CDK2/cyclin A.
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CCAP SYNTHESIS

SOLID PHASE SYNTHESIS

SCHEME 2.1. SYNTHESIS OF THE NOVEL C-TERMINAL CAPPING GROUPS. This scheme illustrates the
route of synthesis for the novel C-terminal capping groups. First the amine underwent reductive amination
to form a secondary amine. Second, the Ncapped peptide was made using solid phase synthesis. Next, the
secondary amine was coupled to the Ncapped peptide in a solution phase coupling reaction. In the final
step, the arginine side chain was deprotected.

FIGURE 2.8. CHEMICAL STRUCTURES OF LEUCINE AND BETALEUCINE. Chemical structures of natural
leucine and non-natural β-Leucine.

2.2.2 DISCUSSION
The replacement of the C-terminal tetrapeptide (RLIF) is necessary for the complete
conversion of HAKRRLIF to a non-peptidic, drug-like inhibitor. The pharmacophore of

39

(R)RLIF was utilized in the AnchorQuery™ software to screen for potential fragment
alternatives for the replacement of this peptide sequence. The AnchorQuery™ software
is of interest because it specializes in pharmacophore search technology to help users
screen for novel PPIs40.
A library of potential C-terminal capping groups have been identified, through
AnchorQuery™, that contains the desired pharmacophore features while maintaining
good complementarity with the primary hydrophobic pocket of the CBG. Mimicking and
preserving the binding determinants of Leu6 and Phe8 is of utmost importance because
these particular residues make important intermolecular interactions with the CBG.
Other important interactions between the CBM and the CBG are the H-bonding of Arg4
with Ile281 and ion-pairing interactions of this residue with Glu220, H-bonds between
Arg5 and Gln254 and charge-charge interactions with Asp283. In addition, the backbone
amide of Leu6 H-bonds with Gln254 while Ile7, of the CBM, acts as a spacer between
Leu6 and Phe8, allowing complementary binding of these two residues in the primary
hydrophobic pocket (Figure 2.9). P
otential Ccaps for the C-terminal tripeptide LIF have been identified using the
AnchorQuery™ software. HAKRRLIF and the receptor (cyclin A) were uploaded into
the software and the desired pharmacophore queries of the C-terminus were set. Figure
2.10 illustrates the pharmacophores that were varied to maximize the number of
potentially viable small molecules returned by the software. In addition, other filters
were applied and varied to refine the fragments returned by the software to those that
most closely mimic the pharmacophore queries of interest. A LeuVal anchor was used to
preserve the side chain functionality of the Leu6 because it was previously determined
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that this residue is the most critical residue in the CBM10b.

Once the preferred

pharmacophore queries (maximum of 20) and filters were set, the query was submitted
and the software searched upwards of 25 million compounds to find small molecules that
were within the specified parameters. The fragments returned by the software can be
viewed interactively on the website or be downloaded as .sdf files to be viewed in
preferred software.
ASP283

ILE281
TRP217
GLN224
GLN254

GLU220
FIGURE 2.9. HAKRRLIF DOCKED INTO THE CBG. The intermolecular interactions of the CBM with the
CBG are illustrated here indicated by the light green dotted lines. The known intermolecular interacts are
as follows: histidine ion-pairs with GLU224, alanine hydrogen bonds with TRP217, the first arginine
hydrogen bonds with ILE281 and GLN254 as well as ion-pairs with GLU220, the second arginine ion-pairs
with ASP283, and leucine hydrogen bonds with GLN254.

The AnchorQuery™ website contains sufficient information for the synthesis of the
potential capping groups. The fragments returned by the software are categorized by the
type of reaction that can be used for their synthesis. The small molecules in the database
are part of a MCR library and these reactions differ from standard sequential syntheses in
that the desired product may be obtained by a “one-pot” method using three or more
starting materials. The single step used has obvious benefits in saving on time and cost
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and the overall yield, simplicity of reaction and purification, safety, and environmental
acceptability41. In MCRs, the starting materials react sequentially rather than at the same
time and it is the irreversible steps that drive the reaction to completion. With MCRs,
more time is spent on the design and development of the experiment compared to
traditional sequential reactions. The most common MCR is the Ugi Reaction (Scheme
2.2). This MCR is a four component reaction that includes an acid component, aldehyde
or ketone, amine component and an isocyanide component41. In the initial step, the
aldehyde or ketone and the amine components condense to form an intermediate imine,
followed by protonation of the acid component to increase the electrophilicity of the
imine bond41. The electrophilic iminium ion and the now nucleophilic conjugate base of
the acid, add to the isocyanide component forming an intermediate acid anhydride (not
shown).

Acid anhydrides are strong acylating agents and following intramolecular

acylation and rearrangement of the hydroxylimine intermediate to an amine the stable
Ugi product is formed41.
Previously it has been reported that RRLIF (SCCP 5811, Table 2.4) has an IC50
value of 1.4±0.42 µM against CDK2/cyclin A and when Arg4 (the first Arg of RRLIF)
was replaced with 35DCPT (SCCP 5773, Table 1.2) the potency decreased by two-fold to
give an IC50 value of 4.0±0.6 µM against CDK2/cyclin A. Also, RRLF (SCCP 5874;
Table 2.4) was reported to have an IC50 value of 24.8±12.66 µM, a decrease in potency of
approximately twelve-fold, against CDK2/cyclin A. Theoretically, if Arg4 (the first Arg
of RRLF) of SCCP 5874 was replaced with 35DCPT (35DCPT-RLF), the IC50 value of
this FLIP compound would be near 50 µM against CDK2/cyclin A. The novel Ccap,
phenylpropyl amine containing FLIP (SCCP 6004; Table 2.3) mimics the binding mode
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of Phe8 and is structurally comparable to the hypothetical structure of 35DCPT-RLF.
SCCP 6004 has an IC50 value of 57.74 µM against CDK2/cyclin A which is comparable
to that of the theoretical IC50 value of 35DCPT-RLF of approximately 50 µM. This
concludes that SCCP 6004 may be the best FLIP compound of this series and the
aromatic ring can further be optimized to regain potency.

FIGURE 2.10. ILLUSTRATIONS OF THE ANCHORQUERY™ PHARMACOPHORE QUERIES. AnchorQuery™
images of the pharmacophore queries that were used for the pharmacophore search. The variations in the
query were as follows: A) Ala2hydrophobic, Arg4positiveion, Leu6hydrophobic, and Phe8hydrophobic, B) Ala2hydrophobic,
Arg5positiveion, Leu6hydrophobic, and Phe8hydrophobic C) Arg4positiveion, Leu6hydrophobic, and Phe8hydrophobic, D)
Arg5positiveion, Leu6hydrophobic, and Phe8hydrophobic, and E) Leu6hydrophobic and Phe8hydrophobic.

SCHEME 2.2. ILLUSTRATION OF THE UGI REACTION. The Ugi reaction is a four component reaction where
an acid component, an aldehyde or ketone, an amine component and an isocyanide are combined to form the
Ugi product.

SCCP 6014 differs from SCCP 6004 by a tertiary amine at the R position, seen in
Table 2.3.

The added ethyl group was originally thought to aid in the
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geometry/conformation of this compound however, the addition of this group has
abolished most of the activity that is shown by SCCP 6004. The ethyl chain may hinder
the activity by steric hindrance, causing a clash with the protein, and resulting in the
lower potency of this FLIP. Perhaps a methyl group would be a better substituent at this
position. With a methyl there would be less steric bulk and potentially would avoid a
clash with the protein. The methyl group would still structurally aid in the geometry of
the compound.
TABLE 2.4. SUMMARY OF PREVIOUSLY REPORTED PEPTIDES AND THEIR ACTIVITY AGAINST
CDK2/CYCLIN A AND CDK4/ CYCLIN D1.

SCCP ID
5811
5874
5875

Peptide
RRLIF
RRLF
RR(βLeu)F

CDK2/Cyclin A
IC50 (µM)
1.4±0.42
24.8±12.66
3.3±2.33

CDK4/Cyclin D1
IC50 (µM)
16.1±1.73
100~180
20.7±12.45

2.2.3 MATERIAL AND METHODS
Individually, HAKRRLIF and cyclin A (PDB 2UUE) were uploaded into the
AnchorQuery™ software, the desired pharmacophore queries of the C-terminal amino
acids (RRLIF) and a LeuVal anchor were selected. The hydrophobic pharmacophore of
Ala2, Leu6, and Phe8 (the 2nd, 6th, and 8th amino acids of the octamer) and the ion-pairing
pharmacophore of Arg4 and Arg5 were varied to obtain numerous small molecules
(Figure 2.10). The capping groups returned by the software all closely mimic the binding
mode of both Leu6 and Phe8. Retaining the SAR of these amino acids is critical in
identifying potential Ccaps to replace LIF of HAKRRLIF.
The initial compound synthesized from the fragments returned by AnchorQuery™
was 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)pentanamide.
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This small molecule

was synthesized in four steps (1) reductive amination, (2) solid phase synthesis, (3)
solution phase coupling, and (4) arginine deprotection (Scheme 2.1). In brief, in a round
bottom the amine (5 mmol; 5EQ; 676.05 mg) and aldehyde (1 mmol; 1EQ; 44.05 mg)
starting materials were coupled via reductive amination in the presents of sodium
triacetoxyborohydride (NaBH(OAc)3); 1.4 mmol; 1.4EQ; 296.72 mg) reducing agent in
dichloromethane (DCM). The reaction was conducted at room temperature (RT) for two
hours. After which 2N sodium hydroxide (NaOH) was added to quench the reaction and
the reaction was left to stir for an additional 10 minutes. The organic and aqueous layers
were separated and the organic layer was removed under reduced pressure and the
product was dried under vacuum. The monoalkylated product was then purified by prepHPLC yielding 74.7 mg (0.1%) of pure product. MS (EI+) 163.
The Ncap, 35DCPT, was prepared by the following procedure. To a solution of
3,5-dichloroaniline (15 mmol; 1EQ; 2.430 g) in a round bottom in 10 mL of methanol
was added 10 mL of 6N hydrochloric acid (HCl) at 0 degrees Celsius. Sodium nitrite (30
mmol; 2EQ; 2.070 g) was then slowly added as a solid. The reaction mixture was stirred
for 15 minutes at 0 degrees Celsius, after which sodium acetate was added as a solid to
adjust the reaction to pH 5. Subsequent to this, a solution of ethyl 2-chloroacetoacetate
(15 mmol; 1EQ; 2.469 g) in 10 mL of methanol was added slowly while the temperature
was maintained at 0 degrees Celsius, after which the reaction mixture was allowed to
warm to room temperature and stirred for 12 hours. The reaction was monitored for
completion by thin-layer chromatography (TLC) with 20 percent ethyl acetate (EtOAc) in
hexanes. Methanol was then removed under reduced pressure, diethyl ether was added,
and the organic layer was separated and washed with saturated sodium bicarbonate and
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water prior to drying over sodium sulfate3. The organic layer was concentrated and the
product was dried under vacuum yielding 2.107 g (47.6%). 1H NMR (chloroform-d, 300
MHz) δ (ppm) 8.2 (s, 1H), 7.1 (s, 2H), 7.0 (s, 1H), 4.36-4.43 (q, J = 5.46 Hz, 2H), 1.381.43 (t, J = 7.05 Hz, 3H).
The second step for the synthesis of 35DCPT is as follows. The step 1 product,
ethyl 2-chloro-2-[2-(3,5-dichlorophenyl)hydrazono]acetate (7.129 mmol; 1EQ; 2.107 g),
and acetaldehyde oxime (7.129 mmol; 1EQ; 0.421 g) were dissolved in toluene and
heated to reflux for 2 h, after which triethylamine (7.129 mmol; 1EQ; 0.721 g) was
added. The reaction was monitored by TLC with 20% EtOAc in hexanes. After
completion, the reaction mixture was then concentrated and partitioned between EtOAc
and water. The layers were separated and the aqueous layer was washed with EtOAc. The
combined organic layers were washed with water and brine, dried with sodium sulfate,
filtered, concentrated and dried under vacuum yielding 2.2818 g (50.7%)3. 1H NMR
(chloroform-d, 300 MHz) δ (ppm) 7.43 (d, J = 9 Hz 3H), 2.57 (s, 3H).
The final step in the synthesis of 35DCPT is as follows. The step 2 product, ethyl
1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylate (7.602 mmol; 1EQ;
2.282 g) was refluxed in NaOH (60.820 mmol; 8EQ; 2.433 g) in a 50/50 mixture of
ethanol and water for 2 h, and the reaction was monitored by TLC (35% EtOAC in
hexanes). After completion, the reaction mixture was cooled, the alcohol was evaporated,
and the mixture was diluted with water. The reaction mixture was acidified with 1 N HCl
and stirred to precipitate the product yielding 1.032 g (25.3%). 1H NMR (chloroform-d,
300 MHz) δ (ppm) 7.50 (s, 1H), 7.45 (s, 2H), 4.46−4.53 (q, J = 7.26 Hz, 2H), 2.62 (s,
3H), 1.41−1.46 (t, J = 7.08 Hz, 3H). MS (EI+) 271.
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Solid phase peptide synthesis was used for the synthesis of 35DCPT-Arg-β-Leu
similar to Section 2.3.3 (Scheme 2.3). In brief, Fmoc protected leucine (1.108 mmol;
2EQ; 391.58 mg) in 5 mL of DCM (10 mL/1 gram resin) and a 2-chlorotrityl resin (0.554
mmol; 1EQ; 480 mg) was mixed in a round bottom at room temperature with N,NDiisopropylethylamine (DIPEA; 5.54 mmol; 1EQ; 715.99 mg) for 5 minutes42. After
which another 1.662 mmol (1.5EQ; 215.06 mg) of DIPEA was added and mixed for an
additional 60 minutes. To endcap any unreacted 2-chlorotrityl groups, HPLC grade
methanol (0.4 mL; 0.8mL/1 gram of resin) was added and stirred for 15 minutes. The
resin was then filtered and washed three times with DCM, twice with dimethylformamide
(DMF), twice with DCM and three times with methanol42. The resin was placed into a
solid phase peptide ynthesis vessel and the Fmoc group of the Leu was deprotected using
20 percent piperidine in DMF while nitrogen was bubbled into the vessel for stirring.
After 30 minutes, the resin was filtered and washed thoroughly with DMF.
The second amino acid, Fmoc-Arginine(Pmc) (1.108 mmol; 2EQ; 764.38 mg) was
added to the vessel in the presence of a coupling agent (O-benzotriazole-N,N,N’,N’tetramethyl-uronium-hexafluoro-phosphate , HBTU; 2.438 mmol; 4.4EQ; 924.587 mg)
and a base, DIPEA (3.324 mmol; 6EQ; 429.59 mg) in DMF and was bubbled with
nitrogen at room temperature for 4-6 hours. Upon a negative ninhydrin test, the resin was
filtered and washed several times with DMF. The Fmoc group was deprotected using 20
percent piperidine in DMF for 30 minutes. The resin was filtered and washed with DMF.
The Ncap, 35DCPT (1.108 mmol; 2EQ; 301.48 mg) was then added to the resin with
HBTU (2.438 mmol; 4.4EQ; 924.587 mg) and DIPEA (3.324 mmol; 6EQ; 429.59 mg) in
DMF and bubbled with nitrogen at room temperature for 4-6 hours. When the reaction
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was complete, the resin was thoroughly washed with DMF. The resin was removed from
the vessel and placed into a round bottom flask to be cleaved using 3-5 percent TFA in
DCM for approximately three minutes. The resin was filtered and rinsed until the resin
returned to a yellow in color and the filtrates was collected and was removed under
reduced pressure and left to dry under vacuum.

The product was purified through

FLASH chromatography yielding 240.10 mg (54%).
In a round bottom, the Ccap 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)
pentanamide (0.272 mmol; 2EQ; 36.78 mg) was coupled the 35DCPT-Arg(Pmc)-Leu
(0.136 mmol; 1EQ; 110 mg) peptide in the presence of HBTU (0.299 mmol; 2.2EQ;
113.47 mg) and DIPEA (0.408 mmol; 4EQ; 52.73 mg). HPLC was used to monitor the
reaction and upon completion the reaction mixture was concentrated and partitioned
between EtOAc and water. The aqueous layer was back extracted with EtOAc. The
organic layers were combined and washed with 1N sodium hydroxide (NaOH), 1N HCl,
and brine (saturated sodium chloride solution). The organic layer was dried with sodium
sulfate (Na2SO4), filter, concentrated, and dried under vacuum. Lastly, the side chain of
the Arg was deprotected using 95:2.5:2.5 TFA:water:TIPS overnight. Once the HPLC
confirmed deprotection the solvents were removed under reduced pressure and the final
product was purified by prep-HPLC resulting 36.0 mg (40%) of SCCP 6004. MS (EI+)
658.

2.3 LEU-PHE MIMETICS
Based on commercially available compounds with appropriate functionality to mimic
both Leu6 and Phe8, FLIPs have been computationally designed (Table 2.5), synthesized
and coupled to 35DCPT-Arg5.

These Leu-Phe mimetics contain either isobutyl or
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isopropyl groups at the R2 position (Table 2.5) to help retain the interactions of Leu6 in
the primary hydrophobic pocket which was shown to be the most important residue of the
CBM. Also, there are varying alkyl groups at the R1 position to mimic Phe8 in the
pocket.

2.3.1 RESULTS
Following solid phase synthesis and coupling with the Ccap, the Leu-Phe mimetics
were purified via prep-HPLC.

As these compounds have a chiral center and were

purchased as a racemic mixture, diastereomers were formed for the FLIPs during
synthesis. However, not all of the FLIP isomers were able to be successfully separated
by prep-HPLC but the diastereomers that were separated the first isomers that eluted
were those that showed activity against CDK2/cyclin A. The isomers with activity would
be the R isomer, as the S isomer would not be expected to have activity against the
CDK/cyclin complexes because only R amino acids have been shown to be active. The
HPLC data and MS data of the purified FLIPs are located in Appendix B. As shown by
HPLC, the FLIP compounds are 79-98 percent pure by UV and the MS results confirm
the identity of desired FLIP compounds. Subsequent to full characterization of the FLIP
compounds their binding affinities were tested via FP assay as described in Section 2.1.4.
Of the FLIPs listed in Table 2.5, only SCCP 5977, 5979 and 5983 showed activity
against CDK2/cyclin A while none displayed significant binding to CDK4/cyclin D1.
The isobutyl group mimicking Leu6, in all the compounds, retained some of the binding
affinity and the various alkoxy groups mimicking Phe8 had a significant effect on the
activity of each FLIP on CDK2/cyclin A. SCCP 5977 contains an isobutyl group to
mimic the Phe8 position in the primary pocket. This compound had an IC 50 value of
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148.4 μM against CDK2/cyclin A. SCCP 5979 has a propyl group reaching in to the
pocket in replacement of Phe8 and has an IC50 value of 181.2 μM against CDK2/cyclin
A. Lastly, SCCP 5983 contains an ethyl group which was shown to be slightly less
potent against CDK2/cyclin A with an IC50 value of 164.02 μM. All other compounds
(SCCP 5978, 5980-5982, 5984, and 5985) are not active against either CDK2/cyclin A or
CDK4/cyclin D1.
TABLE 2.5. SUMMARY OF THE LEU-PHE MIMETICS

SCCP ID
5977

n
0

R1
iBut

R2
iBut

R3
H

CDK2/Cyclin A
IC50 (µM)
148.4

CDK2/Cyclin A
IC050 (µM)
>180

5978

0

iBut

iBut

H

>180

>180

5979

0

Pr

iBut

H

181.2

>180

5980

0

Pr

iBut

H

>180

>180

5981

1

Me

iBut

Me

>180

>180

5982

1

Me

iBut

H

>180

>180

5983

0

Et

iBut

H

164.02

>180

5984

0

Et

iBut

H

>180

>180

5985

0

Me

iBut

H

>180

>180
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2.3.2 DISCUSSION
The computationally designed Ccaps, based on commercially available compounds with
appropriate functionality to mimic both Leu6 and Phe8 of HAKRRLIF, have been
coupled to the 35DCPT-Arg. The binding affinity of these novel Ccaps have been
measured via the FP assay to determine the ability of the FLIP compounds to compete
with a peptidic inhibitor (tracer peptide) against CDK2/cyclin A and CDK4/cyclin D1.
Compounds SCCP 5977, 5979, and 5983 (Figure 2.11) are the only FLIPs out of this
series to show activity against CDK2/cyclin A.

No FLIPs were active against

CDK4/cyclin D1.
The isobutyl group replacement for Phe8 (SCCP 5977) appears to be the best alkyl
group compared to the propyl group (SCCP5979) and the ethyl group (SCCP 5983). The
additional methyl group of the isobutyl seems to be a contributor to the retention of
potency compared to the propyl group. SCCP 5977 showed an IC50 value of 148.4 μM,
SCCP 5979 with 181.2 μM and SCCP 5983 with 164.02 μM against CDK2/cyclin A.
The isobutyl side chain (SCCP 5977) proves to be most potent against CDK2/cyclin A.

FIGURE 2.11. CHEMICAL STRUCTURES OF SCCP 5977, 5979, AND 5983. Listed are the chemical
structures for the Ccaps of SCCP 5977, 5979, and 5983. SCCP 5977 showed an IC 50 value of 148.4 μM,
SCCP 5979 has an IC50 value of 181.2 μM, and SCCP 5983 with an IC50 value of 164.02 μM all against
CDK2/cyclin A. These compounds are not active against CDK4/cyclin D1. The R group for each of these
compounds is 35DCPT-Arg.

We can compare these results to a previously reported FLIP (SCCP 5923; Table
1.3)

that

contains

4CPT-Arg5-Leu6

and
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the

4-(4-fluorophenoxy)pyridin-2-

yl)methanamine Ccap. This FLIP compound has an IC50 value of 18.1±4.0 μM. Section
1.5 introduced both 35DCPT and 4CPT as Ncaps and when coupled to RLIF (5773 and
5774, respectively) showed IC50 values of 4.0±0.6 μM and 11.5±3.3 μM, respectively.
There is a slight difference in the expected binding affinities between SCCP 5979 and
SCCP 5923 due to the different Ncaps but even with these differences SCCP 5923 is still
significantly more potent against CDK2/cyclin A.

2.3.3 MATERIAL AND METHODS
The computationally designed Ccaps have been coupled to 35DCPT-Arg and their
binding affinities have been evaluated in a competitive binding assay. The peptide
synthesis in which these small molecules were synthesized is illustrated in Scheme 2.3.
In a round bottom, an arginine (1.32 mmol; 1EQ; 3.935 g) (protected by Pbf and coupled
to a 2-Chlorotrityl resin) was coupled to 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4triazole-3-carboxamide (35DCPT; 2EQ; 2.64 mmol; 0.718 g) in the presence of a
coupling agent (HBTU, 5.808 mmol; 4.4EQ; 2.202 g) and a base (DIPEA, 7.92 mmol;
6EQ; 1.023 g) in DMF.

The reaction was left to stirr overnight and when HPLC

confirmed the consumption of starting materials the resin was filtered and washed
thoroughly with DMF. The resin was then cleaved with 3-5 percent TFA in DCM for 3
minutes. The resin was then filtered and washed several times with DCM until the resin
returned to a yellow color. The filtrate was collected and the organic layer was removed
under reduced pressure yielding 581.26 mg (64.7%).
The Leu-Phe mimetic Ccaps were then coupled. In brief, 1-(2-isobutoxyphenyl)-3methylbutan-1-amine (0.07346 mmol; 1EQ; 17.29 mg) was coupled to 35DCPTArg(Pbf) (0.07346 mmol; 1EQ; 50 mg) in the presence of HBTU (0.1469 mmol; 2.2EQ;
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55.72 mg) and DIPEA (0.2938 mmol; 4EQ; 37.971 mg) in DCM. The reaction was left
overnight and when HPLC confirmed the consumption of starting materials the reaction
mixture was concentrated and partitioned between EtOAc and water. The aqueous layer
was back extracted with EtOAc. The organic layers were combined and washed with 1N
NaOH, 1N HCl, and brine, dried over sodium sulfate, filtered concentrated, and dried
under vacuum.

Lastly, the side chain of the Arg was deprotected using 95:2.5:2.5

TFA:water:TIPS overnight.

Once deprotection was confirmed the solvents were

removed under reduced pressure.

Due to this compound having a chiral center,

diastereomers were synthesized and were separated by prep-HPLC resulting in 0.940 mg
(0.02%; SCCP 5977) and 1.180 mg (0.025%; SCCP 5978). MS (EI+) 645. The FP assay
was used to measure the binding affinity of these novel Ccaps. In this assay, each FLIP
compound was tested against CDK2/cyclin A and CDK4/cyclin D1.

SCHEME 2.3. GENERAL REACTION SCHEME FOR THE SYNTHESIS OF THE LEU-PHE MIMETICS. As seen
in this scheme, the arginine linker attached to a resin was coupling with the desired Ncap of 35DCPT. This
product was then cleaved from the resin and coupled with the novel Leu-Phe mimetic Ccaps.

.

53

CHAPTER 3
DEVELOPMENT OF FRAGMENT LIGAND INHIBITORY PEPTIDES CONTAINING
NON-NATURAL AMINO ACIDS
In the effort to convert HAKRRLIF into a more drug-like molecule by the REPLACE
strategy, the C-terminal amino acids (RLIF) need to be replaced by small molecules for
the complete conversion of the octamer into a cell permeable, non-peptidic inhibitor.
Chapter 2 describes a valid approach in the replacement of LIF of the octamer. Chapter 3
introduces the replacement of the critical arginine amino acid by an alternative approach.
The replacement of Arg5 has been attempted by the inclusion of non-natural arginine
derivatives. These isosteres have been utilized to explore their effects on the binding
affinity of the FLIP molecules, further establish SAR for this interaction, and potentially
improve drug-likeness through enhancing stability and cell permeability.

3.1 ARGININE ISOSTERES
Isosteric arginine derivatives have been utilized as linkers between 35DCPT and a Cterminal dipeptide, β-Leu-NMethylPhe-NH2. These non-natural amino acids form amide
bonds similarly to natural amino acids but have side chains that distinguish them43. The
non-natural amino acids have been synthesized and incorporated into the FLIP
compounds to enhance pharmacokinetics and the inhibitory activities of peptides37a. The
library of non-natural arginine derivatives obtained may (1) potentially mimic the
interactions that are made between the CBM (Arg5) and the CBG (Asp283), (2) evaluate
the steric requirements of this position, (3) improve drug-like properties, and (4) most
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likely improve the binding affinity of the FLIPs through favoring increased ion-pairing
interactions. Currently, structure-activity relationship (SAR) data for this interaction is at
the initial stages. The replacement of Arg5 with various amino acids has been done with
activity still present however at a decreased amount of 4-fold or greater. The arginine at
this position is important for the binding affinity of HAKRRLIF and therefore varying
the functionality of these arginine derivative side chains will aid in the further
development of the SAR and possibly the replacement for this position.

3.2 RESULTS AND DISCUSSION
The arginine isosteres listed in Table 3.1 were Fmoc-protected prior to solid phase
synthesis with the dipeptide Ccap, β-Leu-NMethylPhe-NH2. These FLIPs were then
Ncapped with 35DCPT. The alkylation of the guanidine group in these isosteres provide
functionality and should protect the guanidine groups from reacting during peptide
synthesis. These side chains are expected to interact with Asp283 of the CBG and help
establish further SAR.
Peptides composed of naturally occurring amino acids are useful as lead
compounds in discovering new drug therapies but generally speaking are limited as
therapeutics by their undesirable pharmacokinetic profiles. These are caused by their
poor permeability (blood brain barrier, cell membrane, etc.) and lack of metabolic
stability including protease-mediated degradation37. While naturally occurring amino
acids are not ideal for novel drug therapies, their non-natural counterparts allow
modification to improve drug-likeness. Appropriate non-natural amino acids, such as
these arginine isosteres, can be incorporated into compounds in order to increase
lipophilicity

and

potentially

improve
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the

pharmacokinetic

parameters,

the

agonist/antagonist behaviors, and may promote ion-pairing37a.

This ion-pairing

interaction is enhanced by incorporating alkyl groups on the side chains of guanidine
containing residues. The alkyl groups destabilize solvation of the charged side chain
promoting ion-pairing and the binding to the target44.
TABLE 3.1. SUMMARY OF THE ARGININE ISOSTERES

R

The incorporation of non-natural amino acids can allow compounds to evade
peptidase digestion thus creating a more stable compound44. Having a more stable
compound should result in an increased half-life of the compound in the circulatory
system of patients44.

This improved stability can potentially be achieved through

modifications to the side chains of amino acids and may include, but are not limited to,
the incorporation of halogens, unsaturated hydrocarbons, heterocycles, silicon, and
organometallic units45.

By adding appropriate non-natural amino acids in the non-

peptidic inhibitor, functionality can be incorporated to help enhance pharmacokinetic
parameters, enhance the inhibitory abilities of peptides and promote favorable ion-pairing
37a, b

.

Varying the side chains can also provide SAR data to further optimize the
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functionality of these side chains.
Non-natural arginine derivatives, gifted to the McInnes lab from the Dix laboratory
at the Medical University of South Carolina, have been utilized to replace Arg5 of the Cterminal pentapeptide (RRLIF; Table 3.1). The side chains of these arginine derivatives
contain functional groups such as acyclic (methyl and ethyl) and cyclic (4,5-dihydro-1Himidazole and 1,4,5,6-tetrahydropyrimidine) groups.

These groups may provide

protection to the guanidine group to elude reactivity during peptide synthesis. These
modified guanidines will help establish further SAR data for the interactions between the
Arg5 of the CBM and Asp283 of the CGB.
The arginine derivatives have been Fmoc-protected prior to solid phase peptide
synthesis with a C-terminal dipeptide, β-Leu-NMethylPhe-NH2 and Ncapped with
35DCPT. The C-terminal dipeptide has been previously tested in the FP assay as RR(βLeu)NMePhe-NH2 (SCCP 5941) and is a potent inhibitor of CDK2/cyclin A with an IC50
value of 0.405±0.091 µM. To incorporate this C-terminal dipeptide with the current
isosteres, the natural arginine was been replaced with an arginine derivative. The identity
of the Arg isostere-dipeptide was confirmed by Liquid Chromatography-Mass
Spectrometry (LCMS), was Ncapped with 35DCPT and the final FLIP compound was
cleaved from the resin but the M+S did not confirm the desired product but indicates that,
in this case, the guanidine group was able to react readily with the activated 35DCPT and
resulted in double Ncapped FLIP compounds (Appendix C). During purification two
peaks were isolated and identified through MS. The first isolated peak has an m/z of
1010 (Appendix C; C1) which theoretically corresponds to the addition of 35DCPT
twice. It is believed that the additional Ncap is coupled to the guanidine side chain;
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further analysis will confirm the exact structure that relates to this mass. The other
fraction that was isolated has an m/z of 559 (data not shown). This mass corresponds to
35DCPT-βL-NMethylF indicating that the addition of the arginine isosteres was not
complete.
To address this issue several different parameters will be varied to elude such
outcomes. During the initial synthesis 35DCPT was used in excess and the reaction
occurred overnight. To resolve the current issue, the Ncap and Arg isosteres-dipeptide
will be used at the same scale (1:1 ratio) and the reaction will be monitored closely
through HPLC until the starting materials are consumed. If the guanidine still proves to
be readily reactive, protection of this group will be employed. Common protecting
groups for guanidines are 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) and
2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc). The addition of the sulfonamide group
masks the reactivity of the guanidine and these groups are easily removed with high
concentrations of acid.

3.3 MATERIALS AND METHODS
Following the synthesis of the arginine derivatives, the amine group on the alpha carbon
was protected by 9-Fluorenylmethyl N-succinimidyl carbonate (Fmoc-O Suc) via Fmoc
protection in aqueous solution. For example, N-methyl arginine (1.328 mmol; 1EQ; 250
mg) was combined with Fmoc-O Suc (1.859 mmol; 1.4EQ; 627.10 mg) in a 3:1 ratio of
water and ethanol46. The reaction mixture was stirred for 4 to 6 hours at 60 degrees
Celsius.

Once complete, the reaction mixture was cooled to zero degrees Celsius,

acidified to pH 4-5, and extracted with EtOAc46. The aqueous layer was evaporated
under reduced pressure and purified by FLASH chromatography.
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The Fmoc-N-methyl arginine was then coupled to 35DCPT and a C-terminal
dipeptide sequence of β-Leu-NMethylPhe-NH2 via solid phase peptide synthesis (Scheme
3.1). In brief, Fmoc protected Rink Amide Resin (0.75 mmol; 1EQ; 1.19 g) was preswelled in DMF for 30 minutes. The resin was then placed into a solid phase peptide
synthesis vessel, and the Fmoc group protecting the resin was deprotected with 20%
piperidine in DMF for 30 minutes47. The resin was then filtered and rinsed thoroughly
with DMF. Fmoc-N-MethylPhe (1.5 mmol; 2EQ; 0.6022 g) was then coupled using dry
DMF, HBTU as the coupling agent (3.375 mmol; 4.4EQ; 1.280 g), and DIPEA as base
(4.5 mmol; 6EQ; 0.5816 g) with nitrogen was bubbled into the vessel for stirring. After 4
to 6 hours a ninhydrin test confirmed consumption of the starting material and the resin
was filtered and rinsed several times with DMF and the Fmoc group was deprotected
using 20% piperidine in DMF under nitrogen. Next, the Fmoc-β-Leu (1.5 mmol; 2EQ;
0.5512 g) was coupled in the same manner and the Fmoc protecting group was
deprotected.
The Fmoc-N-methyl arginine (0.561 mmol; 5EQ; 0.230 g) was coupled to the
dipeptide-resin (0.112 mmol; 1EQ; 0.277 g) for 24 to 36 hours in the presence of HBTU
(1.008 mmol; 11EQ; 382.27 mg), DIPEA (1.380 mmol; 15EQ; 178.35 mg), DNF and
nitrogen was bubbled into the vessel for stirring. When the ninhydrin test confirmed the
consumption of the starting materials, the resin was then filtered and washed thoroughly
with DMF. The Ncap, 35DCPT, (0.240 mmol; 2EQ; 0.0653 g) was then attached by the
same procedure for 12 hours. To complete the synthesis, the rink amide resin was
removed from the vessel, placed into a round bottom and was cleaved using 20% TFA in
DCM for 20 minutes and rinsed several times with DCM. Following resin cleavage, the
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filtrate was collected and the organic solvent was removed under reduced pressure. The
product was purified by prep-HPLC and tested in the FP assay for their binding.

SCHEME 3.1. GENERAL REACTION SCHEME FOR THE PEPTIDE SYNTHESIS OF THE ARGININE ISOSTERS.
An amide rink resin was deprotected and coupled with the coupled with NMethyl-Phe and β-Leu. This
dipeptide was then coupled with an arginine isosteres and Ncapped with 35DCPT. These peptides were
synthesized via solid phase peptide synthesis.
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CHAPTER 4
ALTERNATIVE APPROACHES AND THE FUTURE
DIRECTION OF CDK INHIBITORS
SECTION 4.1 ALTERNATIVE APPROACHES
Another strategy for the development of CDK inhibitors for use in oncology beyond
targeting the ATP binding pocket and the cyclin binding groove is to inhibit the
formation of the CDK/cyclin complex. Such inhibitors interfere with the protein-protein
interface between CDK2 and cyclin A. Cyclin A binds to CDK2 by interacting with the
N- and C-terminal lobes through PPI48. When the α3 and α5 helices of cyclin A bind to
the PSTAIRE helix of CDK2 major conformational rearrangements occur resulting in an
inactive intermediate complex48. This process is the initial step in the CDK/cyclin
complex formation followed by a gradual conformational reorganization to expose the T
loop of CDK2. The T-loop is then phosphorylated by the cyclin activating kinase (CAK)
to form the substrate binding site48. A peptide was developed, C1, based on the α5
helices of the cyclin, to target this interface and has shown to inhibit CDK2/cyclin A
activity towards histone H1 and pRb fused with GST48. A derivative of this peptide, C4,
containing a point mutation to increase solubility, was shown to inhibit CDK2 kinase
activity when associating with either cyclin A or cyclin E48. Figure 4.1 illustrates the
binding placement for C4 on the cyclin subunit. However, CDK1/cyclin B, protein
kinase A and protein kinase C were not affected by C448. C4 was shown to adopt an αhelical conformation that mimics the hydrophobic interactions between CDK2 and cyclin
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A and this is understood as to how the inhibition of this complex occurs48. C4 promotes a
conformational change that induces the CDK2/cyclin A complex into an inactive
conformation and was shown to not bind to pre-existing CDK2/cyclin A complexes or
free CDK248. Concluding that C4 is potentially a selective inhibitor of CDK2/cyclin A
and this was validated when tested in estrogen-independent MDA-MB-231 breast cancer
cells48. C4 was able to completely inhibit cellular proliferation48.

FIGURE 4.1. ILLUSTRATION OF A CDK/CYCLIN COMPLEX. A. The ATP binding site is located on the
CDK and the cyclin binding groove on the cyclin. C4 and NBI1 bind to the interface between CDK2 and
cyclin A. [Reprinted with permission from Orzaez, M., A. Gortat, et al. (2009). "ATP-noncompetitive
inhibitors of CDK-cyclin complexes." ChemMedChem 4(1): 19-24. ] B. The three major sites discussed in
this section are illustrated; α5 helix, PSTAIRE, and the T-loop all located on the interface between CDK2
and cyclin A. [Gondeau, C., S. Gerbal-Chaloin, et al. (2005). "Design of a novel class of peptide inhibitors
of cyclin-dependent kinase/cyclin activation." The Journal of biological chemistry 280(14): 13793-13800.]

A second compound, NBI1, has also been identified as a CDK2/cyclin A inhibitor
that targets neither the ATP binding pocket nor the CBG48. NBI1 is a hexapeptide that
contains all D-amino acids and is known to only interact with the cyclin subunit by
binding to the region containing the α3, α4, and α5 helices, illustrated in Figure 4.148-49.
NBI1 showed an IC50 value against CDK2/cyclin A of 1.1 µM49 and it is believed that
NBI1 affects the stability of the CDK/cyclin complex48. Inhibition of CDK2/cyclin A
results in elevated E2F-1 activity leading to cell cycle arrest in S phase resulting in
apoptosis49. Unlike C4, NBI1 was shown to inhibit CDK1/cyclin B and CDK6/cyclin D3
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but did not show inhibition against a panel of other serine/threonine protein kinases48. A
derivative of NBI1, TAT-NBI1 (TAT is a cell penetrating carrier), was tested against
numerous cell lines at various concentrations and CDK1 and CDK2 activities were
significantly decreased whereas CDK4 was only minimally inhibited and demonstrated to
have cells arrest in the S or G2/M phases48. TAT-NBI1 in a concentration and time
dependent manner inhibited cell proliferation by inducing S phase arrest and apoptosis in
glioblastoma, colon, and ovarian cancer cells49.
NB11 has been proven to be a selective inhibitor of the association between
CDK2/cyclin A with remarkable affinity however, this small molecule is a weak inhibitor
of CDK2/cyclin E49. Both cyclins associate with the same CDK therefore the different
selectivity between the two complexes must be due to structural differences amongst the
cyclins49.

This suggests that the development for an alternative inhibitor for the

inhibition of CDK2/cyclin E is necessary. A potential advantage of targeting the CBG is
the inhibition of all the cell cycle CDKs due to the conserved sequence recognition
(CBM) across cyclins A, E and D-type.

SECTION 4.2 FUTURE DIRECTIONS
The REPLACE methodology has successfully aided in the identification of novel Ccaps.
The most potent FLIP compound reported here is SCCP 6004 with an IC50 value of 57.74
µM against CDK2/cyclin A. The Ccap of this FLIP and many other potential Ccaps were
identified by the AnchorQuery™ software. The fragments chosen for the work in this
thesis closely mimic the position of Leu6 and Phe8 in the primary hydrophobic pocket.
The software also returned a similar small molecule to 2-amino-N-ethyl-4-methyl-N-(3phenylpropyl)pentanamide (Ccap of SCCP 6005 and 6014; Figure 2.7). This fragment 3-
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amino-N-phenethyl-3-phenyl-N-(2,2,2-trifluoroethyl)propanamide (Figure 4.2) and is of
interest to further build the SAR. The trifluoroethyl group of this small molecule could
be replaced with a small alkyl group because it does not make intermolecular interactions
within the pocket, although having a group at this position may be important
geometrically. The aromatic ring positioned in the Leu6 position is expected to have a
binding mode similarly to Leu6 and be space-filling.

FIGURE 4.2.
POTENTIAL FRAGMENT SUPERIMPOSED WITH HAKRRLIF IN THE PRIMARY
HYDROPHOBIC
POCKET.
3-amino-N-phenethyl-3-phenyl-N-(2,2,2-trifluoroethyl)propanamide
superimposed with HAKRRLIF in the primary hydrophobic pocket. This small molecule closely mimics
the pose of LEU6 and PHE8 and therefore is a potential Ccap of interest.

Based on the results from the Ccaps tested in Chapter 2, a series of Ccaps have
been designed that are of interest (Table 4.1).

These Ccaps (Table 4.1) will be

synthesized and undergo solid phase synthesis similarly to that which is illustrated in
Scheme 2.1. The Ccaps (No. 1-4) differ from SCCP 6000 – 6005 and 6014 (Table 2.3)
by the group in the Leu6 position which is either leucine or β-leucine. The new Ccaps
will contain phenylalanine, histidine, β-phenylalanine, or β-histidine depending on the
length of the alkyl chain at the n2 position seen in Table 2.3. These derivatives will help
further establish the SAR for the Leu6 position. The variation of the ring size plus the
addition of potential ion-pairing interaction of the imidazole ring of histidine will aid in
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the determination of which functional group(s) would best retain or enhance the binding
affinity of this position. Leu6 has previously been determined to be the most critical
amino acid of the octamer (HAKRRLIF) and therefore its replacement has been
challenging but has also been shown that this position is capable of being replaced with a
small molecule.
SCCP 6004 has shown to be the most potent FLIP of the compounds reported here.
SCCP 6004 has been structurally modified (Table 4.1; No. 5-8) to help regain activity
that was lost due to fragment replacement. These modified FLIP compounds will contain
the addition of halogens on the aromatic ring at either the 4-position or the 3,5-position.
Previously, a library of bis(aryl) ether Ccaps were generated. The first of this series was
a FLIP compound contained 4CPT-RL-(3-phenoxyphenyl)methanamine (SCCP 5807)
showed an IC50 value of 106.1±26.2 µM against CDK2/cyclin A. Following the addition
of halogens on the aromatic ring the binding affinities for these compounds increased 2-5
fold compared to SCCP 5807. SCCP 5824 and 5823 (Table 1.3) contain fluoro groups at
the 3 and 4 position with IC50 values of 53.2±11.6 µM and 18.1±4.0 µM against
CDK2/cyclin A, respectively.
Of Table 4.1, compounds No. 5 and 7 contain a chlorine and fluorine at the 3 and 5
positions, respectively. Modeling these compounds using Discovery Studio showed that
the addition of halogens to these fragments does not clash with the protein and therefore
may potentially enhance the current activity of SCCP 6004. Compounds No. 6 and 8 have
either a chlorine or fluorine at the 4 position of the aromatic ring, respectively. Having a
chlorine at this position severely clashed with the protein when structurally designed in
Discovery Studio and thus a compound containing this functional group may result in a
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loss of activity that SCCP 6004 currently has. The fluorine at the 4 position however has
a good complementarity with the binding pocket. Such compounds will be tested in the
competitive binding assay to determine the effects of halogenation.
TABLE 4.1. SUMMARY OF C-TERMINAL CAPPING GROUPS OF INTEREST.

No.

n1

n2

1

0

3

2

1

3

3

0

3

4

1

3

5

0

3

6

0

3

7

0

3

8

0

3

R1

R3

R4

R5

H

H

H

H

H

H

H

H

H

H

H

H

Cl

H

Cl

H

Cl

H

F

H

F

H

F

H

SECTION 4.3 PREDICTION OF CELLULAR ACTIVITY OF NOVEL CCAPPED FLIPS
The work reported here has identified a series of FLIP compounds that further validate
the REPLACE methodology through the replacement of the C-terminal amino acids with
fragments that have IC50 values comparable to those previously reported. With further
modification these Ccaps have the potential to be 2-fold or more potent than the bis(aryl)
ether Ccaps which has an IC50 value of 18.1±4.0 µM against CDK2/cyclin A. The next
major step in this project is to generate cell permeable compounds.
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Mendoza et al. (2003) reported that RXL peptides have the ability to block the
recruitment of E2F-1 and its phosphorylation through the inhibition of CDK2/cyclin A as
well as selectively promote apoptosis in cells with deregulated CDK4/6-cyclin D-INK4pRb pathway50. The peptides PVKRRLDL and PVKRRLFL were coupled to fusion
peptides (penetratin) to promote entry into cells50. During standard cell viability assays
both PEN-PVKRRLDL and PEN-PVKRRLFG peptide inhibited the proliferation of an
osteosarcoma (U2OS) cell line in a concentration-dependent manner50.
Cell proliferation assays were conducted in house with HeLa (p53 defective),
prostate cancer Du145 (pRb null), and osteosarcoma U2OS (p16 defective which should
upregulate E2F-1 activity) cell lines. Peptides containing the fusion peptide or peptide
alone showed that both a peptide alone (SCCP 5995; SAKRR-βL-3TA-G) and a
scrambled fusion peptide (SCCP 5991; PEN-ETDHQYLAESS) have no effect on growth
inhibition, both with IC50 values greater than 100 µM (Table 4.2). A weakly binding
control (SCCP 5990; PEN-PVKRRAFG) shows growth inhibition against all three cell
lines with IC50 values of 49.9±0.6 μM (HeLa), 24.9±1.9 µM (Du145) and 42.5±1.9 μM
(U2OS).

A positive control (SCCP 5994; PEN-SAKRR-βL-3TA-Gly) has growth

inhibition in only Du145 (38.5±4.3 µM) and U2OS (43.1±1.1 μM) cell lines. SCCP 5989
a fusion peptide used by Mendoza et al. (2003) with the peptide sequence of PENPVRRLFG showed to have an IC50 values of approximately 30 µM in all three cell lines.
Efforts are also being made to put FLIP compounds with well-established
competitive binding assay IC50 values into cancer cell lines. Prostate (DU145) and
osteosarcoma (U2OS) cell lines have been treated with SCCP 5963 and 5964 (Table 4.3).
These FLIPs showed IC50 values of 6.49±0.27 µM and 7.91±5.08 µM against
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CDK2/cyclin A, respectively. When DU145 prostate cells were treated with SCCP 5963
and 5964 the IC50 values obtained were 36.5±2.6 µM and 21.8±0.32 µM, respectively.
The U2OS osteosarcoma cells had similar results with IC50 values of 30.7±2.7 µM for
SCCP 5963 and 18.3±1.5 µM for SCCP 5964. SCCP 5963 has comparable growth
inhibition compared to SCCP 5989 however, SCCP 5964 has a greater growth inhibition
than SCCP 5989.
TABLE 4.2. SUMMARY OF VARIOUS PEPTIDE ACTIVITIES IN CELL LINES.

SCCP
5990
5995
5989
5991

HeLa
IC50 (μM)
49.9±0.6
>100
30.3±1.4
>100

Du145
IC50 (μM)
24.9±1.9

U2OS
IC50 (μM)
42.5±1.9

32.3±3.2
>100

28.9±2.2
>100

5994

>100

38.5±4.3

43.1±1.1

To aid in the prediction of cell permeability, ADMET (absorption, distribution,
metabolism, excretion, and toxicity) parameters have been calculated for SCCP 5963,
5964, and 6004 as well as the new FLIP compounds of interest for the future (Table 4.4).
ADMET parameters such as solubility between 0-1, absorption between 3-4, Lipinski’s
Rule of 5 (molecular weight (MW) <500, logP <5, the number of hydrogen bond donors
(HBD) <5, and the number of hydrogen bond acceptors (HBA) <10), the number of
rotatable bonds (≤10), and the polar surface area (PSA) (≤140) are ideal for cell
permeability. SCCP 5964 (Table 4.4) was the most active in the cell proliferation assay
and when compared to SCCP 5963, it has a more ideal solubility level, lowest logP value,
fewer HBA and fewer rotatable bonds but has the highest PSA.
The most active compound from the novel Ccaps reported here is SCCP 6004.
This FLIP has comparable solubility and absorption levels and has fewer HBD, HBA,
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and rotatable bonds to SCCP 5964. The logP value for SCCP 6004 is significantly higher
than that of SCCP 5964 and has almost 1.5 fold less PSA. This may conclude that SCCP
6004 will be more cell permeability compared to SCCP 5964. With these ADMET
values it can be predicted that SCCP 6004 will have greater cell permeability but may
have slightly less activity based on its binding affinity in the FP assay.
TABLE 4.3. SUMMARY OF FLIP ACTIVITY IN COMPETITIVE BINDING AND CELL PROLIFERATION
ASSAYS

Competitive Binding Assay

Cell proliferation Assay

CDK2/Cyclins A
IC50 (µM)

CDK4/Cyclins D1
IC50 (µM)

DU145
IC50 (µM)

U2OS
IC50 (µM)

Me

6.49±0.27

>100

36.5±2.6

30.7±2.7

H

7.91±5.08

>100

21.8±0.32

18.3±1.5

SCCP

R1

5963

5964

R2

The FLIP compounds of interest for the future also have comparable solubility and
absorption levels (Table 4.4). Compounds No. 3 and 4 have comparable logP values and
lower PSA values than SCCP 5964 which may indicate a slight increased in cell
permeability. All other FLIPs have greater logP values, similar number of HBD, HBA
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and rotatable bonds, and lower PSA values. This may contend that these FLIPs may have
cell permeability and activity but will most likely not be greater than that of SCCP 5964.
Compound No. 6 has the highest logP value (without exceeding the limit of 5) and one of
the lowest PSAs, therefore this FLIP can be predicted to be the most cell permeable of
Table 4.4).

Polar Surface
Area
(≤140)
214.21
251.25
181.65

Polar Surface
Area
(≤140)

Number of
Rotatable Bonds
(≤10)
18
18
17
Number of
Rotatable Bonds
(≤10)

Number of HBA
(<10)
14
14
12
Number of HBA
(<10)

Number of HBD
(<5)
8
9
8
Number of HBD
(<5)

logP
≤5
3.163
2.255
4.044

logP
≤5

Absorption
Level
(3-4)
3
3
3

Absorption
Level
(3-4)

Solubility Level
(0-1)
2
1
2
Solubility Level
(0-1)

714.292
706.233
658.279

Molecular
Weight
(<500)

Future Ccaps of Interest

SCCP
5963
5964
6004

Molecular
Weight
(<500)

TABLE 4.4. ADMET RESULTS FOR CURRENT AND FUTURE FLIPS.

1
2
3
4

706.279
692.263
682.254
696.64

2
2
2
2

3
3
3
3

4.510
4.054
2.398
2.083

8
8
9
9

12
12
14
14

18
17
17
17

181.65
181.65
210.33
210.33

5
6
7
8

726.201
692.240
694.260
676.269

1
1
1
2

3
3
3
3

5.373
4.708
4.455
4.250

8
8
8
8

12
12
12
12

17
17
17
17

181.65
181.65
181.65
181.65

No.

As for the arginine isosteres, changing the functionality at this position affects
mainly logP and PSA (Table 4.5). The solubility and absorption levels remain consistent
with the altered side chains and the number of HBD, HBA, and rotatable bonds are
comparable across the table. However, the PSA values decrease by 13 to 25 units and the
logP values increase with added functionality. With the increase in logP and the decrease
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in PSA, these arginine isosteres are expected to be promising replacements for natural
arginine. Theoretically, if arginine isosteres 2 or 3 were introduced into a compound like
SCCP 5964 the cell permeability and potentially the activity would increase due to the
effects of the altered side chain.

Solubility
Level
(0-1)

Absorption
Level
(3-4)

logP
≤5

Number of
HBD
(<5)

Number of
HBA
(<10)

Number of
Rotatable
Bonds
(≤10)

Polar
Surface
Area
(≤140)

Structure of
Side Chain
Natural Arg

Molecular
Weight
(<500)

TABLE 4.5. RESULTS FOR ARGININE ISOSTERES.

116.12

5

0

0.308

5

3

4

63.64

130.13

5

0

0.514

4

3

5

49.65

144.15

4

0

0.720

3

3

5

38.03

144.15

5

0

0.863

4

3

6

49.65

142.13

4

0

0.538

3

3

4

38.03

156.15

4

0

0.601

3

3

4

38.03

1

2

3

4

5

SECTION 4.4 CONCLUSIONS
There are frequent deregulations of endogenous CDKIs in human cancers and the
development of novel CDK inhibitors is being investigated by targeting the CBG.
Currently, non-peptidic inhibitors are being developed based on the HAKRRLIF which is
derived from the C-terminal peptide sequence of the CDK inhibitor p21WAF1. Reported
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here, computational design (structure- and pharmacophore-based) and the incorporation
of arginine isosteres have been utilized to identify PLAs to replace the C-terminal amino
acids (RLIF) by the REPLACE methodology. These FLIPs have been synthesized,
coupled with a potent Ncap, and their binding affinities have been tested using an FP
assay. Of the FLIP compounds generated, SCCP 6004 was determined to have the
greatest potency against CDK2/cyclin A with and IC50 value of 57.74 µM. Furthermore,
ADMET values have been calculated for SCCP 6004 for the comparison with a known
cell permeable FLIP, SCCP 5964. SCCP 6004 may have comparable or greater cell
permeability than SCCP 5964 however further optimization of SCCP 6004 is needed for
this compound to be more active in cells. ADMET values were also calculated to
compare natural arginine with the arginine isosteres listed here. Isostere number 2 is
expected to have the greatest impact on cell permeability and cellular activity if it were to
be incorporated into a compound similar to SCCP 5964.
The results reported here have enhanced the development of a selective, drug-like,
cell permeable CDK inhibitors by generating promising Ccaps and by identifying a novel
approach for the design of PLAs. Furthermore, these results bring this project closer to
achieving the ultimate goal of developing a novel class of cancer therapeutics based on
cell cycle inhibition.
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APPENDIX A
ANCHORQUERY™ IDENTIFIED CCAP CHARACTERIZATION
SCCP 6000

A1.
MS results for N-((2S)-1-((1-(benzylamino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-1oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6000). MS(ES):
m/z: 644 [M+H]+ (100%)

A2.
HPLC trace of N-((2S)-1-((1-(benzylamino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-1oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6000).
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SCCP 6001

A3. MS results for N-((2S)-1-((1-(benzyl(ethyl)amino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-1oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6001). MS(ES):
m/z: 672 [M+H]+ (100%)

A4. HPLC results for N-((2S)-1-((1-(benzyl(ethyl)amino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino1-oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6001).
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SCCP 6002

A5.
MS
results
for
1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((5-methyl-1-oxo-1(phenethylamino)hexan-3-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6002). MS(ES): m/z: 658 [M+H]+ (100%)

A6.
HPLC
results
for
1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((5-methyl-1-oxo-1(phenethylamino)hexan-3-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6002). MS(ES):
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SCCP 6003

A7. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(phenethyl)amino)-5-methyl-1-oxohexan-3yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide
(SCCP
6003).
MS(ES): m/z: 686 [M+H]+ (100%)

A8.
HPLC results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(phenethyl)amino)-5-methyl-1oxohexan-3-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6003).
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SCCP 6004

A9.
MS
results
for
1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((4-methyl-1-oxo-1-((3phenylpropyl)amino)pentan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide
(SCCP 6004). MS(ES): m/z: 658 [M+H]+ (100%)

A10.
HPLC results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((4-methyl-1-oxo-1-((3phenylpropyl)amino)pentan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide
(SCCP 6004).
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SCCP 6005

A11. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6005). MS(ES): m/z: 686 [M+H]+ (100%)

A12. HPLC results for 1 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6005).
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SCCP 6014

A13. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6014). MS(ES): m/z: 686 [M+H]+ (100%)

A14. HPLC results for 1 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP
6014).
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A TABLE 1.

SCCP

Purity

Column
Dimensions

Flow
Rate

HPLC
RT

Theoretical
MW

6000

>92.7%

4.6 × 250 mm

1ml/min

29.37

644.60

6001

>98.0%

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

31.07

672.65

6002

>90.0%

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

30.25

658.62

6003

>98.0%

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

31.47

686.67

6004

>95.0%

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

30.50

658.62

6005

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

6014

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

Method
5-95% acetonitrile/water/
0.1%TFA
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APPENDIX B
LEU6/PHE8 MIMETIC CHARACTERIZATION
SCCP 5977 and 5978

B1.
HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-isobutoxyphenyl)-3methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5977 and 5978).

B2.
MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-isobutoxyphenyl)-3methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5977 and 5978).
MS(ES): m/z: 645 [M+H]+ (100%)
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SCCP 5979 and 5980

B3.
HPLC
trace
of
1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((3-methyl-1-(2propoxyphenyl)butyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5979
and 5980).

B4.
MS
results
for
1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((3-methyl-1-(2propoxyphenyl)butyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5979
and 5980). MS(ES): m/z: 631 [M+H]+ (100%)
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SCCP 5981

B5. HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxy-5-methylphenyl)-3methylbutan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5981).

B6. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxy-5-methylphenyl)-3methylbutan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5981).
MS(ES): m/z: 617 [M+H]+ (100%)
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SCCP 5982

B7. HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3-methylbutan2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5982).

B8. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3-methylbutan2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5982). MS(ES): m/z:
603 [M+H]+ (100%)
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SCCP 5983 and 5984

B9.
HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(2-ethoxyphenyl)-3-methylbutyl)amino)-5guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5983 and 5984).

B10. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(2-ethoxyphenyl)-3-methylbutyl)amino)-5guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5983 and 5984). MS(ES):
m/z: 617 [M+H]+ (100%)
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SCCP 5985

B11.
HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5985).

B12. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5985). MS(ES):
m/z: 603 [M+H]+ (90%)
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B TABLE 1.

SCCP

Purity

Column
Dimensions

Flow
Rate

HPLC
RT

Theoretical
MW

5977

>79.20

4.6 × 250 mm

1ml/min

46.63

645.62

5978

>83.50

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

47.42

645.62

5979

>97.70

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

44.35

631.60

5980

>96.00

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

45.42

631.60

5981

>98.00

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

41.18

617.57

5982

>98.00

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

39.07

603.54

5983

>82.90

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

41.82

617.57

5984

>98.00

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

41.72

617.57

5985

>82.60

4.6 × 250 mm

5-95% acetonitrile/water/
0.1%TFA

1ml/min

40.62

603.54

Method
5-95% acetonitrile/water/
0.1%TFA
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APPENDIX C
SCCP 6010 CHARACTERIZATION

C1. HPLC trace of N-((2S)-1-((1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-5-methyl-1oxohexan-3-yl)amino)-5-((1-(1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carbonyl)-1,4,5,6tetrahydropyrimidin-2-yl)amino)-1-oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3carboxamide.

C2. MS results for N-((2S)-1-((1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-5-methyl-1oxohexan-3-yl)amino)-5-((1-(1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carbonyl)-1,4,5,6tetrahydropyrimidin-2-yl)amino)-1-oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3carboxamide. MS(ES): m/z: 1010 [M+H]+ (10-15%)
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